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ABSTRACT
A purification scheme was devised for human glutathione S-transferase (GST) pi that
resulted in a high yield of homogeneous protein from human placenta, lung and
erythrocytes. Polyclonal antisera against GST pi from lung and placenta were raised in
eight rabbits. The GST pi proteins purified from placenta, lung and erythrocytes were
found to have identical isoelectric points (pi =4.8) and subunit molecular weights
(Mr=24 800), and were found to be immunologically identical. The antibody
demonstrating the best specificity and sensitivity was employed to develop a
radioimmunoassay (RIA) for the measurement of GST pi.
Using the RIA, GST pi concentrations were measured in the plasma of patients
diagnosed as having cancer of the bronchus. Concentrations of the enzyme were
significantly higher (P<0.01) than those measured in a control group of patients with
respiratory disorders other than malignancy. To prevent spuriously high results for
GST pi concentrations caused by platelet release, the blood for analysis was collected
into 'Thrombotect' tubes, which contain inhibitors of platelet activation.
The RIA developed for GST pi and also existing RIA for GST B,, GST B2 and GST p
were used to determine GST levels in a variety of biological fluids and tissues.
Measurement of the individual GST isoenzyme expression in normal and tumour
cytosol prepared from human lung, colon and stomach showed that the concentration
of GST pi was significantly increased in tumour tissue relative to paired normal tissue.
The expression of GST B, and GST B2, the predominant isoenzyme in normal liver,
kidney and stomach, decreased dramatically in tumour tissue from these organs. In
breast cancer cytosols significant differences in GST expression were also observed
between oestrogen receptor-rich and oestrogen receptor-poor tumours. The proportion
of individuals with cancer found to express the polymorphic GST isoenzyme GST p
was not significantly different from the expression rate of the isoenzyme in control
populations. The expression of the various GST isoenzymes in development showed
that there was a decrease in GST pi expression in liver and lung as the fetus matured,
while the alpha class GST showed an increase in expression throughout development.
Purification of GST isoenzymes from bronchoalveolar lavage and gall bladder bile by
affinity chromatography showed that GST pi constituted the major isoenzyme in bile,
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and it is postulated that GST pi acts as a carrier protein of toxic, non-substrate, iigands
to remove as yet unidentified substances from biliary epithelial cells and prevent their
reabsorption. Concentrations of GST B, and GST B2 were found to be significantly
raised (P<0.02) in bronchoalveolar lavage fluid obtained from the suspected abnormal
area of lung compared with the presumed normal area of lung, in patients later
diagnosed as having cancer of the bronchus, whilst in patients with non-malignant
respiratory disorders no significant difference in GST concentration was found.
Plasma GST B, measurements were used to investigate hepatocellular integrity in
adults following hypoglycaemia and in children exposed to isoflurane or halothane
anaesthesia. Hypoglycaemia produced a significant increase in plasma GST B,.
Abnormalities in plasma GST B, were greater in children receiving halothane compared
to the children who received isoflurane.
These studies indicate that GST pi measurements by RIA may provide a useful tumour
marker for cancer of the bronchus, whilst GST B, measurements in bronchoalveolar
lavage may be useful in the diagnosis of suspected lung malignancy. The studies on
plasma GST B! measurements confirm previous studies that suggested such
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The multiple isoenzymes of the glutathione S-transferases (GST; EC 2.5.1.18) catalyse
the conjugation of reduced glutathione (GSH) with numerous electrophilic, hydrophobic
compounds in the first step of mercapturic acid formation (Boyland and Chasseaud,
1969). These isoenzymes are often present in high cellular concentrations, thus the
relatively low substrate specificities and catalytic efficiencies reported for GST are
counterbalanced by the abundance and versatility of these enzymes. Such qualities
appear well suited to a family of proteins whose function is to protect cells against the
toxic effects of the multitude of exogenous or endogenous compounds that may be
encountered. This family of GST enzymes may also be involved in the biosynthesis of
leukotrienes and prostaglandins (Mannervik et al., 1984; Christ-Hazelhof et at., 1976).
Certain GST isoenzymes also exhibit peroxidase activity and are able to reduce
diverse organic hydroperoxides to their respective alcohols. Potential substrates
including fatty acids and DNA which have been subject to peroxidation, hence the
peroxidase activity of GST may represent part of a repair mechanism for both DNA and
lipids (Ketterer etal., 1987).
In addition to their catalytic functions, the GST also exhibit ligand binding
properties for a variety of organic compounds such as bilirubin, steroids and bile salts.
A property reflected in a previous term for certain GST isoenzymes 'ligandin'. Thus
GST may serve as intracellular storage sites or transport proteins for hydrophobic
compounds, including both xenobiotics and endogenous metabolites.
In the last decade numerous publications have been concerned with the
properties of the GST enzymes and the factors which are involved in their regulation
and expression. As each GST isoenzyme provides a protection against a different
spectrum of toxic chemicals, particular emphasis has surrounded the possible role of
GST enzymes in drug resistance, whether it be intrinsic or acquired (Review: Hayes
and Wolf, 1988). Several models have been studied, and it has been shown that
increased resistance to cytotoxic insult can be accompanied by over-expression of
GST enzymes.
Another related area where GST involvement has been under study is in its
possible role in carcinogenesis. With elevated levels of the GST pi isoenzyme being
reported in tumour tissues and preneoplastic lesions (Sato et al., 1984). Thus the
plasma measurement of GST pi isoenzyme, may have a role as a tumour marker for
diagnosing or monitoring the progression of certain cancers. The plasma
measurements of the GST isoenzymes GST B, and GST B2 have already been shown
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to be sensitive markers of hepatic integrity (Beckett and Hayes, 1987).
1.01 : Glutathione: the substrate
Glutathione is a tripeptide with the sequence, /-glutamic acid-cysteine-glycine and
may exist in the reduced (GSH) or oxidised (GSSG) form (figure 1a). The /-glutamyl
linkage between the N-terminal glutamate and the cysteine is unusual in peptides and
it is thought that this may provide a mechanism of resistance to degradation by cellular
proteases. GSH has a net negative charge at physiological pH and is highly water
soluble with the nucleophilic thiol group able to interact with electrophilic compounds.
Glutathione is ubiquitous in eukaryotic cells being implicated in a number of
cellular functions. It is the most prevalent cellular thiol and the most abundant low
molecular weight peptide present in cells. Glutathione acts as a reducing agent and
an antioxidant, serves as reservoir for cysteine, participates in detoxification reactions
for xenobiotics and metabolism of numerous cellular compounds, is required for the
synthesis of some prostaglandins and leukotrienes, and may be involved in cell cycle
regulation (Meister and Anderson, 1983; Deneke and Fanburg, 1989).
In man the reduced form of glutathione is present in cells in concentrations
ranging from 0.5 to 10 mmol/L depending on the organ, compared to the much lower
concentrations of the oxidised form (4 to 10 pmol/L). Hepatocellular concentrations of
GSH are maintained by achieving a balance between the rate of synthesis and the rate
of utilization. GSH may be formed either from reduction of the oxidised form by
glutathione reductase or by the direct synthesis from constituent amino acids
(Kaplowitz et al., 1985).
Many enzymes utilize GSH as a substrate including glutathione peroxidase,
glutathione reductase, glyoxalase, glutathione transhydrogenase and glutathione S-
transferase.
Conjugation of electrophilic xenobiotics with the sulphur atom of GSH by GST
usually results in a decrease in the reactivity and toxicity and an increase in the
solubility of the compound. The conjugation of xenobiotics or endogenous metabolites
with GSH is the first step in the formation of mercapturic acids, which may be readily
excreted into urine (Boyland and Chasseaud, 1969). The anionic nature of GSH and


















Figure 1a: The inter-relationship of reduced glutathione with oxidised glutathione
(glutathione disulphide; GSSG) and their chemical structures.
[ (1), y-glutamyl peptide link]
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1.02 : The Mercapturic acid pathway
The mechanism of mercapturic acid biosynthesis and the involvement of GSH
conjugates was established in 1959 (Barnes et al., 1959; Bray et al., 1959a,b) and a
comprehensive review of the role of GSH and GST in mercapturic acid biosynthesis
was described by Boyland and Chasseaud (1969). Briefly the thioesters, formed by
the reaction catalysed by GST, are converted to mercapturic acids in three separate
stages (figure 1b):
1) The removal of the y-glutamyl moiety by the action of y-glutamyl-
transferase.
2) The removal of glycine by the action of a dipeptidase.
3) The N-acetyl-CoA linked acetylation of the cysteine conjugate to form
a N-acetylcysteine thioether, which is the mercapturic acid.
Hepatic GSH conjugates and catabolites are excreted in bile. There may be further
catabolism in the intestine, and conjugates may undergo enterohepatic circulation
and/or be excreted in the faeces (Chasseaud, 1976). Because of their high solubility,



































Figure 1 b: Conjugation of an electrophilic compound (FIX) with glutathione is
catalysed by glutathione S-transferase (the conjugate may be excreted
directly into bile). Catabolism of non-excreted or reabsorbed
glutathione conjugates usually takes place in the kidney where y-
glutamyl transferase catalyses the transfer of the y-glutamyl moiety to
neutral amino acids (AA) or peptides. After which, cysteinyl-glycinase
(dipeptidase) catalyses the hydrolysis of the cysteinyl-glycine peptide
bond, with the release of glycine. The cysteinyl derivative can then be
converted by N-acetyl transferase to a mercapturic acid by N-acetylation
with acetyl CoA (AcCoA). Alternatively, the cysteine conjugate can be
converted to the thiol derivative, pyruvate and NH3 by cysteine
conjugate /S-lyase.
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1.03 : Historical overview of the GST
The publication of the paper The reaction of 1,2-dihydronaphthalene and 1,2-epoxy-
1,2,3,4-tetrahydronaphthalene', by Booth et al. (1960), was of particular importance as
it was the first paper to report enzymic catalysis of GSH conjugation by the rat-liver
soluble supernatant fraction (cytosol). The following year Booth et al. (1961)
demonstrated GST activity in rat liver cytosol with a number of electrophilic substrates,
including 1,2-dichloro-4-nitrobenzene, benzyl chloride, bromoethane and
bromsulphthalein. In the same year Coombes and Stakelum (1961), also showed that
rat-liver cytosol catalysed the GSH conjugation of bromsulphthalein.
Shortly after these initial reports, it was recognised that several types of GST
activity occurred in rat liver. The enzyme(s) that catalysed the conjugation of GSH with
aromatic halogen and nitro compounds, was different from the GST which catalysed
the conjugation of GSH with aliphatic halogen compounds (Johnson, 1963) and the
various forms of GST that were described, were named according to the type of
reaction that they catalysed (Boyland and Chasseaud, 1969; Chasseaud, 1974).
Hence, glutathione S-aryltransferase conjugated GSH to aromatic and other cyclic
compounds containing labile halogens or nitro groups, glutathione S-alkyltransferases
utilized alkylhalides as substrates, glutathione S-aralkyltransferases were specific for
aralkylhalides and esters and, glutathione S-epoxide transferase conjugated various
epoxides with GSH. At the time when this nomenclature was employed homogeneous
enzyme preparations were not available but as various GST were purified it became
evident that the separate dimeric isoenzymes had overlapping substrate specificities
and the nomenclature based on the structure of the substrate was abandoned.
The development of affinity chromatography matrices such as glutathione-
Sepharose (Simons and Vander Jagt, 1977) and S-hexylglutathione-Sepharose
(Guthenberg et al., 1979) greatly facilitated the purification of GST isoenzymes and in
conjunction with chromatofocusing has meant that many new GST forms have been
identified and characterized in species as diverse as plants (Mozer et al., 1983),
bacteria (Di llio et al., 1988a), yeast (Tamaki et al, 1989), insects (Jansen eta/., 1982),
fish (Nimmo, 1987) as well as, numerous mammals including man.
At the same time as the early experiments on GST isoenzymes were being
reported, reports were accumulating concerning a cytosolic protein from rat liver which
had a high affinity for various endogenous and exogenous organic anions. Ketterer et
al. (1967) isolated a carcinogen-binding protein named 'basic azo-dye carcinogen-
binding protein (5-ABP)'. Morey and Litwack (1969) isolated a Cortisol metabolite
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binding protein termed 'Corticosteroid Binder I' and Levi et al. (1969) isolated a
bilirubin- and bromsulphthalein-binding protein called 'Y protein'. After collaboration
between the three laboratories it was found that these proteins were identical and the
protein was renamed 'Ligandin' (Litwack et al., 1971). As ligandin was shown to be
capable of binding a large number of organic anions, it was proposed that ligandin
functioned as a carrier protein transferring hydrophobic and anionic compounds such
as bilirubin and bile salts across the hepatocyte for excretion into the bile (Levi et al.,
1969; Reyes et al., 1971; Fleischner et al., 1972). Ligandin was also shown to bind
covalently certain carcinogens, notably azo-dye carcinogens and metabolites of
polycyclic hydrocarbons (Ketterer et al., 1967; Ketterer, 1972).
Although Kaplowitz et al. (1973) demonstrated an association between
bromsulphthalein binding to ligandin and its conjugation with glutathione, the
discovery that ligandin was a GST is accredited to Jakoby and colleagues in
collaboration with Arias and his group who reported that ligandin was identical to
glutathione S-transferase B (Habig et al., 1974). The relationship between ligandin and
GST in the literature, has been complicated by the fact that many of the early
preparations of the protein were heterogeneous GST mixtures. Hayes etal., (1979)
demonstrated that ligandin was in fact a homodimer comprising Ya subunits
(nomenclature introduced by Bass et al., (1977) see Table 1a.) whereas, GST B was
found to be heterodimer comprising Ya and Yc subunits. The term 'Ligandin' is now
seldom employed to describe this cytosolic binding protein and care is required when
interpreting historical data, since different laboratories may not be describing the same
protein.
1.04 : Nomenclature of the GST
As mentioned in the previous section the first classification system of cytosolic GST
based on differences in substrate utilisation (Boyland and Chasseaud, 1969) was soon
found to be inappropriate and replaced. The purification scheme devised by Habig et
al. (1976), for the isolation of distinct GST isoenzymes from rat liver, described several
isoenzymes named AA, A, B, C, D and E but even this scheme failed to resolve all the
GST forms which occur in rat liver not to mention extra-hepatic forms. Thus the GST
nomenclature based on this method was incomplete and later superseded.
The cytosolic GST isoenzymes are dimeric and it was their quaternary structure
that provided a basis for the rat nomenclature used currently, the various GST being
named after the subunits from which they comprise. This system of nomenclature was
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introduced by Bass et al. (1977), who named the major subunits of the soluble
bromsulphthalein-binding Y fraction of rat liver as Ya, Yb and Yc, according to their
mobility on SDS/PAGE. The subunit mobility system has been adopted widely and has
been modified to include Yb, and Yb2, Yf, Yk and Yn, and Yn2 (Hayes, 1984, 1986;
Hayes and Mantle, 1986a; Ishikawa et al., 1987) as these additional subunits were
identified. The relative mobilities of the subunits on SDS/PAGE in 12.5%
polyacrylamide resolving gels are Yf>Yk>Ya>Yn>Yb>Yc (Hayes, 1986; Hayes and
Mantle, 1986a). An alternative nomenclature, where subunits were assigned Arabic
numerals, was proposed by Jakoby et al. (1984). The relationship between both forms
of current rat nomenclatures is shown in table 1 a which also includes some trivial GST
designations.
The human GST isoenzymes first purified were denoted by Greek letters and
allocated to three classes, based on isoelectric points, and termed basic, neutral and
acidic. The first isoenzymes to be identified were named as follows: five enzymes with
basic isoelectric points called GST a, fi, y, <5 and e (Kamisaka et al., 1975); two
neutral GST termed GST p (Warholm et al., 1981) and GST and three acidic GST
from erythrocytes, placenta and lung termed p (Marcus et al., 1978), n (Guthenberg
and Mannervik, 1981) and A (Hayes et al., 1986) respectively. As more human GST
isoenzymes were described, it was found that they did not fit readily into the basic,
neutral or acidic classes, and Mannervik et al. (1985) introduced the alpha, mu and pi-
classification scheme, based on structural, immunological and enzymatic properties, to
describe mammalian (species-independent) GST isoenzymes that shared similar
qualities. In man the GST isoenzymes have the following homodimeric structure:
alpha-class GST, Ya-type subunits; mu-class GST, Yb-type subunits; and pi-class GST,
Yf-type subunits.
The human alpha-class GST were originally described by Kamisaka et al.
(1975), who purified five basic GST forms (a, p, y, d and e) from liver and postulated
that these enzymes were encoded for by a single gene and the multiple forms were
generated by a postsynthetic modification, possibly deamination. Stockman et al.
(1985,1987) also using human liver, purified and characterized three basic GST
termed GST B1B1, GST and GST B2B2, the subunits B, and B2 being products of
separate genes. This proposal has been validated by subsequent amino acid
sequence data (Hayes et al., 1989) and DNA sequence informaJon (Tu and Qian,
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1986; Rhoads et al., 1987). The B^,, B2B2 and B,B2 correspond to GST e, y and 6.
In the original papers of Beckett and Hayes where the development of
radioimmumoassays for GST B, and GST B2 subunits are described (Hayes et al.,
1983; Beckett and Hayes, 1984), the GST B, and GST B2 subunits were called basic
and N/A2b respectively; the term N/A standing for neutral/acidic. The confusion over
the GST B2 nomenclature arose because it was retained by the diethylaminoethyl
(DEAE-) anion exchanger and was therefore wrongly thought to have a neutral/acidic
isoelectric point. The terms GST B, and GST B2 are used throughout this thesis when
referring to specific subunits, whereas alpha GST isoenzymes refers to the class of
isoenzymes composed of YaYa type subunits.
Alpha-class GST isoenzymes have been reported to be present in a number of
extra-hepatic organs such as kidney (Tateoka et al., 1987), testis (Aceto et al., 1989)
and prostate (Tew et al., 1987) these isoenzymes probably corresponding to those
identified in liver (comprising YaYa type subunits). One exception to this was a report
of the identification of a novel GST (isoelectric point = 9.9) in human skin homologous
with class alpha GST YcYc in the rat (Del Boccio et al., 1987).
The human pi-class GST has been identified in all tissues so far examined.
This pi-class GST has been referred to as "GST-jt and "GST-P" when isolated from
placenta, "GST-A" when isolated from lung, and "GST-/?" when isolated from
erythrocytes. The general name acidic GST (because of its low isoelectric point,
pi=4.8) has also been used. Only one gene for GST pi has been demonstrated
(Cowell et al. 1988), also the studies undertaken here (section 3) have shown that GST
pi purified from placenta, lung or erythrocytes is indistinguishable immunologically.
Throughout this thesis, I use the term GST pi to refer to this acidic GST isoenzyme,
comprising YfYf type subunits, irrespective of its tissue of origin.
The majority of the literature concerning the mu-class GST (comprising YbYb
type subunits) has concerned the GST enzyme GST p and its allelic variant GST
However, other enzymes have been described and these are discussed more fully in
Section 7.
A completely separate Zymogram-based nomenclature scheme for human
cytosolic GST isoenzymes has also developed based on a report by Board (1981),
who, using starch-gel electrophoresis of cell extracts coupled with a GST activity stain,
reported the existence of 3 separate GST loci termed GST1, GST2 and GST3. Further
loci have been identified termed GST4, GST5 (Laisney et al., 1984) and GST6 (Suzuki
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et at., 1987), this nomenclature is discussed further in Section 7 and its relationship
with individual subunit composition and alpha, mu and pi-class illustrated in table 1 b.
In addition to the cytosolic GST enzymes, a human microsomal GST has been
described (McLellan et al., 1989), which is distinct in that it is a trimeric protein with
three identical subunits of molecular weight 17300.
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Table 1a: Alternative nomenclatures for the cytosolic GST subunits in the rat.
The T designation is the system based on Bass et al. (1977). The
numerical designation is that proposed by Jakoby et al. (1984) and
the family designation is based on the proposal of Mannervik et al.
(1985).
"Y* designation Numerical designation Trivial name Family
YaYa 1-1 Ligandin** alpha
YaYc 1-2 b" alpha
YcYc 2-2 aa* alpha
YkYk 8-8 K" alpha
YIYI 10-10 alpha
YoYo 11-11 mu
Yb,Yb, 3-3 a* mu
Yb,Yb2 3-4 C* mu
Yb2Yb2 4-4 D* mu
YnYn 6-6 N" mu
Yb,Yn 3-6 P" mu
Yb2Yn 4-6 S" mu
NO 5-5 E* mu
YfYf 7-7 P(YpYp)*** P«
ND represents no designation.
represents nomenclature employed by Fjellstedt et al., 1973; Habig et al.,
1974, 1976.
represents nomenclature employed by Hayes et al., 1979; Hayes, 1984, 1986.
Kitahara ef al., 1984.
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1.05 : The structure and function of GST
The quaternary structure of cytosolic GST is based on the combination of two subunits
from the same class. To date, GST with a dimeric combination of subunits from
separate classes (alpha, mu or pi) have not been isolated nor has in vitro hybridization,
after denaturation, been demonstrable (Boyer et al., 1983). Why the cytosolic GST
exist as dimers is not known, since it has been shown that individual subunits function
independently and, from a catalytic viewpoint, there appears to be no reason why the
GST should comprise more than one polypeptide (Mannervik, 1985).
Conjugation of electrophilic compounds with GSH involves interaction of the
separate substrates with the GST enzyme, at distinct binding sites. Jakobson et al.
(1977) proposed that each subunit contains an active centre composed of two binding
sites, one with a high affinity for GSH, the other a hydrophobic pocket specific for the
second electrophilic substrate. The catalytic mechanism by which GST afford an
increased rate of conjugation with electrophiles is considered to be simple proximity
effect, as the rate of enhancement of the reactions is not great, and the majority of the
reactions may proceed non-enzymatically (Jakoby, 1978).
1.06 : Types of reaction catalysed by GST
The reactions catalysed by the GST are generally nucleophilic attack of GSH on
various electrophiles. Electrophilic carbon in various forms is susceptible to GSH
conjugation by one or more of the GST isoenzymes. For example, the GST catalyse
GSH conjugation with epoxides, alkyl and aryl halides, and ring opening of lactones.
Addition of GSH to activated alkenes and related compounds are also common.
Displacements of molecules at elements other than carbon are also known, for
example organic nitrates where the GSH attacks the electrophilic nitrogen and organic
thiocyanates where the GST catalyse the nucleophilic attack by GSH on the sulphur
atom.
The alpha-class GST have also been shown to exhibit peroxidase activity
against organic peroxides. This activity of GST is referred to as selenium-independent
glutathione peroxidase activity or Type II glutathione peroxidase activity, to distinguish
it from the activity catalysed by the seleno-enzyme, glutathione peroxidase (Type I).
Other reactions also implicated to involve GST include steroid isomerisation,
where GSH is not consumed but acts as a co-enzyme, the formation of prostaglandin
D from prostaglandin endoperoxides and the biosynthesis of leukotriene C4
monomethyl ester from leukotriene A4 methyl ester. For a review of the majority of
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these reactions see Chasseaud (1979).




















1.07 : Model substrates and inhibitors for GST subunit identification
Since many of the conjugation reactions of electrophiles with GSH may be followed
spectrophotometrically, the catalysis effected by GST can be estimated simply.
Individual cytosolic GST isoenzymes have been shown to display a distinctive
spectrum of catalytic activities with certain substrates and substrates which can
differentiate individual classes of GST have been described. These specificities are
listed in table 1c, with the alpha-class demonstrating a high specific activity for
Cumene hydroperoxide and A5-Androstene-3,17-dione, the mu-class having a high
specific activity towards Bromsulphthalein and fra/7s-4-Phenyl-3-butene-2-one and the
pi-class showing high a specific activity for the diuretic Ethacrynic acid.
The specific activities for the 'model' substrate for GST, 1-chloro-2,4-
dinitrobenzene are also included, to highlight that each class of human GST exhibit
markedly different specific activities even towards this 'model' substrate.
In addition to the individual subunits having distinctive catalytic properties, with
regard to substrate specificities, they also differ with respect to inhibition of activity by
various compounds. The use of specific inhibitors augments the use of various
substrates to discriminate between GST subunits. The most frequently used inhibitors
include Cibacron blue, Triphenyltin chloride, Bromsulphthalein, Haematin, Bilirubin
and various Bile acids (Tahir and Mannervik, 1986).
Table 1c: Specific activities of human GST enzymes. Taken from Stockman et al.
(1987) and Warholm et al. (1983). ND represents not determined.
specific activity (ymol/min/mq)
Substrate GST alpha mu Pi
Ethacrynic acid 0.16 0.22 1.22
Cumene hydroperoxide 92 ND 0.11
A5-Androstene-3,17-dione 8.0 0.12 0.01
Bromsulphthalein <0.002 0.01 <0.01
frans-4-Phenyl-3-butene-2-one 0.0 0.45 0.02
1 -Chloro-2,4-dinitrobenzene 117 272 212
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1.08 : GST as transport proteins
The suggestion that hepatic anion transport involves the GST frequently appears in the
literature and the mechanism of non-covalent binding of substances such as haematin,
bromsulphthalein, bile salts and bilirubin, has been investigate by a number of
research groups using a variety of methods including equilibrium dialysis and
chromatography, quenching of intrinsic tryptophan fluorescence, circular dichroism and
inhibition kinetics (Strange ef a/., 1976,1977; Hayes and Mantle, 1986b; Listowsky et
a/., 1988). Despite numerous studies controversy still persists regarding the nature
and number of binding sites for each isoenzyme subunit.
The GST (primarily ligandin, alpha-class) have been implicated in bilirubin
uptake, not only by binding studies but also from physiological observations. Levi et
al., (1969,1970) suggested that the unconjugated hyperbilirubinaemia, frequently found
in neonatal humans and monkeys, results from a hepatic deficiency of Y protein
(Ligandin), because in monkeys the amount of Y protein was significantly lower during
fetal and early neonatal life than at 5 days after birth. The increase in the
concentration of Y protein at 5 days coincided with the development of efficient
clearance of bromsulphthalein from plasma. It has also been suggested that GST may
have a role in the intrahepatic transport of conjugated bilirubin. In a case report of a
17 year-old male patient with Rotor's syndrome (mild, fluctuant conjugated-
hyperbilirubinaemia) (Adachi and Yamamoto, 1987) it was found that the patients
hepatic GST activity towards 1-chloro-2,4-dinitrobenzene reduced to about 0.2% of the
mean activity of patients with other diseases.
Although the binding of bile salts to GST has received considerable attention,
with the possible exception of lithocholic acid, it appears unlikely that GST act as
carrier proteins for bile acids across the hepatocyte (Strange, 1984). Simple diffusion
is a more likely mechanism of bile acid transport. The theory that GST may have a role
in the intracellular transport of haem (a hydrophobic molecule produced in the inner
mitochondrial membrane) has also been refuted recently (Kirschner-Zilber era/., 1989),
these workers using cultured cells, finding no association between haem synthesis and
GST levels.
Listowsky etal., (1988) investigated the binding of thyroid and steroid
hormones, polycyclic aromatic hydrocarbons and related compounds to GST, and
reported binding of broad specificity but low affinity was evident in many cases. This
report suggested that GST, due to its high intracellular concentration, acted as a kind
of intracellular safety net for many of these hydrophobic compounds, since if the levels
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of the ligand exceed the capacity of the specific receptor or if there was no specific
receptor (in the case of xenobiotics) cytotoxic effects would result unless binding to
GST occurred.
1.09 : Covalent binding of carcinogens by GST
The GST are reported to reduce the susceptibility of the liver to carcinogenesis, not
only through their ability to detoxify carcinogens but also by their ability to bind
covalently highly electrophilic compounds. Azo-dye carcinogen metabolites and
activated metabolites of 3-methylcholanthrene have been shown to combine with rat
ligandin (Ketterer et a!., 1976). The Ya/Yc-containing GST are not the only GST
subunits shown to be capable of this 'suicidal' defence mechanism. The Yb subunits
from rat liver have been implicated in the covalent binding of ethacrynic acid (Yamada
and Kaplowitz, 1980).
It has thus been speculated that GST function in three separate ways to protect
against chemically induced hepatocarcinogenesis.
1. The direct detoxification of the carcinogenic insult.
2. The binding of excess adrenal or gonadal steroid hormones which
may affect the activation of carcinogens.
3. The sacrificial covalent binding of the carcinogen to facilitate its
excretion.
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1,10 : Measurement of GST B, as a sensitive marker of liver damage
The investigation of patients with suspected liver disease depends not only on a
careful case history, physical examination but also on a number of laboratory tests.
The use of ultrasound or radiological investigation may also be required and in a
proportion of cases a liver biopsy may also be performed for histological examination.
The standard biochemical tests used often involve a test of the structural integrity of
the liver (serum transaminase), its ability to transport anions from blood to bile
(bilirubin and bile salt concentrations) a measurement of cholestasis (alkaline
phosphatase and /-glutamyl transferase) and a test of hepatic protein synthesis
(serum albumin concentrations and prothrombin time). Collectively these
measurements are often referred to as 'liver function tests' although they do not all
assess actual hepatic function and should more correctly be referred to as markers of
liver damage. Also, many of these tests are not specific and may be abnormal in a
variety of pathological conditions not affecting the liver. In addition to these commonly
employed tests many others have been advocated, often for specific conditions
examples being, caeruloplasmin for Wilsons disease, a-fetoprotein for
hepatocarcinoma and a-1 -antitrypsin in inherited disorders.
Following tissue damage enzymes and proteins are released from the cell into
plasma and the measurement of the catalytic activity of intracellular enzymes after they
have been released into the peripheral circulation is thus an established technique for
assessing tissue damage in clinical enzymology. Characteristics required by an
enzyme to function as a good biochemical marker include; tissue specificity, high cell
to plasma ratio, ease of measurement and a suitable half life in the blood stream.
Properties that make the measurement of GST B, subunits by RIA an attractive
candidate for assessing hepatic integrity include:
1) The immunohistochemistry of human liver has shown alpha GST to
be uniformly distributed across the liver hepatocytes (Hiley et a!., 1988),
whereas the aminotransferases are mainly periportal in location.
2) Its high concentration in human liver cytosol. As reported in Section 6 of
this thesis, GST B, concentrations of up to 3% of the total cytosolic protein
were measured.
3) High organ specificity. In the adult liver GST B, is normally expressed at
around 5-fold greater concentrations than the level found in kidney, the
kidney being the only other organ to express significant amounts of alpha
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GST, although other tissues do express low levels of these isoenzymes (see
Section 6).
4) The GST are not membrane bound and have a low molecular mass
(52 000 daltons), therefore can be readily released into the circulation.
5) The short half-life of alpha GST in plasma. This property was recognised
by Sherman et al. (1983a) who used RIA measurements of 'ligandin'
(probably total GST B, and GST BJ to monitor the changes in liver function
that occurred in 68 patients with acute viral hepatitis. Sherman et al. (1983a)
concluded that the short-half life of GST in plasma weakens its use as a
diagnostic test in acute viral hepatitis. However, because of its short half-life
(approximately 1 h) the measurement of GST B, or GST B2 provides useful
information concerning the progress of active disease and makes it an ideal
marker for acute hepatocellular damage.
6) Alpha GST levels correlate well with liver histology in chronic active
hepatitis, whereas AST activities show no such correlation (Sherman et al.,
1983a).
As an alternative approach to measuring catalytic activity, mass measurement by
immunological techniques such as RIA or enzyme immunoassay may be used. Both
methods have theoretical advantages and disadvantages. Enzymic activity
measurements are generally rapid and convenient to perform on automated equipment,
such as centrifugal analyzers, and if the appropriate assay conditions are selected
considerable sensitivity may be achieved. However, activity may be decreased by the
presence in plasma of circulating inhibitors, and differentiation between different
isoenzymes may be difficult. Immunoassay methods for the measurement of the
enzyme concentration are not usually affected by the presence of endogenous
inhibitors or activators and if suitable antisera are available immunologically distinct
isoenzymes can be measured, thus providing potentially improved tissue specificity for
the test. Unfortunately, immunoassay techniques are usually slow and labour intensive
since they do not readily lend themselves to automation. Both activity and
immunoassay methods have been reported for the estimation of GST levels in plasma
or serum.
The first substrates, used to determine GST activity in rat tissue, included 1,2-
dichloro-4-nitrobenzene (Booth et al., 1961) and bromsulphthalein (Coombes &
Stakelum, 1961). These two compounds were substrates for rat Yb subunits but could
20
not act as substrates for most other GST subunits including the human alpha-class
found in liver. With the introduction of CDNB, a substrate that is active with most forms
of GST (Clark et al., 1973), the measurement of GST activity in human serum became
an attractive possibility as a sensitive index of liver integrity, especially after Kamisaka
et al. (1975) demonstrated that up to 3% of human liver cytosolic protein was
composed of GST. However even with CDNB, it was difficult to obtain sufficient
sensitivity to permit precise measurement of the activity of GST in plasma or serum.
Measurement of GST activity is susceptible to two main sources of error.
Firstly, there are various non-substrate ligands that bind to GST and inhibit enzymic
activity; physiologically important examples are bile salts (see section 10) and bilirubin
(Simons and Vander Jagt, 1980). The concentrations of these ligands in plasma are
often elevated in liver disease and, as a consequence, they may suppress GST activity
to levels which lie within the reference range. Secondly, platelets, erythrocytes, white
cells, muscle, lung and many other tissues all contain significant quantities of GST pi
which may leak into plasma in health and in a variety of non-hepatic diseases. GST pi
not only reacts with CDNB but it does so with a higher specific activity than that of the
alpha-class GST (Stockman et al., 1987). Thus if CDNB is used as a substrate, poor
organ specificity results. Haemoglobin released from erythrocytes inhibits GST activity
with CDNB (Harvey and Beutler, 1982) and also interferes with monitoring the
coiorimetric reaction therefore, haemolysis invalidates GST activity measurements.
Despite all these potential problems a study on GST activity in human serum has been
reported (Adachi et al., 1980), however, the results were disappointing, with sensitivity
appearing to be the main problem. Adachi et al. (1980) found in acute hepatitis
abnormal serum GST activity could only be found when ALT activity exceed 5 times
the upper reference limit.
The introduction of immunoassay methods for the determination of specific
GST isoenzymes in plasma has resulted in an improved sensitivity over the enzymatic
methods. The first report of a RIA for GST was that of Bass et al. (1977); these
workers developed an assay for measuring rat 'ligandin' (alpha-class GST). The RIA
was used initially to estimate the tissue distribution of 'ligandin in the rat and the
changes that occurred in tissue after the rats had been treated with phenobarbital.
Shortly after, the same group used the RIA to measure the concentration of 'ligandin' in
rat plasma following the production of hepatocellular necrosis by carbon tetrachloride
(Bass et al., 1978). The workers found that plasma 'ligandin' increased at a greater
rate and to higher levels than aspartate aminotransferase (AST) activity following the
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administration of carbon tetrachloride or after bile duct ligation. In both situations the
plasma 'ligandin' returned to normal levels when AST remained elevated.
The first RIA for human 'ligandin' was developed by Tsuru et al. (1978) who
found elevated concentrations of the protein in a variety of liver disorders. However,
there was still considerable overlap between concentrations measured in controls and
in patients with liver disease. The method of Tsuru et al. (1978) showed poor
sensitivity, and it was not possible to define the lower reference limit; the upper limit of
the reference range was 5.3 pg/L. Sherman et al. (1983a, 1983b) described an RIA
method for human 'ligandin' that allowed measurement in normal plasma, but this too
was not sufficiently sensitive to define its lower limit of the reference range; the upper
limit for the reference was 12 pg/L. Subsequently assays with good sensitivity and
precision were described for both GST B, and GST B2 subunits (Beckett and Hayes,
1984).
The assays described for GST B, and GST B2 by Beckett and Hayes (1984)
had two main advantages over previous immunoassays. Firstly, Beckett and Hayes
had available antisera which were able to differentiate between the different basic
subunits, GST B, and GST B2, previous assays for 'ligandin' probably measured both
subunits. Secondly, Beckett and Hayes (1984) employed the technique of delayed
tracer addition, which resulted in improved sensitivity of approximately three-fold. The
reference range quoted for GST B, in 28 healthy volunteer subjects was 1.2-4.1 pg/L
while, the GST B2 reference range was 0.6-1.8 pg/L and for the first time a significant
correlation (r = 0.80) was described between alanine aminotransferase (ALT) levels
and GST B, concentrations in normal subjects. Two studies have shown the
measurement of plasma GST B, isoenzyme to be more sensitive in assessing hepatic
damage compared to the measurement of the GST B2 isoenzyme (Beckett et al., 1987
& 1989a) and in no study where both isoenzymes have been measured have the GST
B2 levels proved to be more informative than the GST B, levels. This is probably
accounted for by the fact that the GST B, isoenzyme is the major alpha-class GST
expressed in majority of adult livers. Therefore, in this thesis only plasma GST B, was
measured as a test of liver damage.
Although the measurement of GST levels by RIA have advantages over
enzymatic methods as far as sensitivity is concerned the time taken to perform a RIA
(about 40 h) is considerable compared with the time taken for an enzyme
measurement of ALT or total GST activity (about 15 min). Enzyme immunoassay
methods, utilising fluorescent labelled substrates, that could be performed in one day
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for anionic and cationic GST have been described (Hirano et al., 1984) but, their
precision and sensitivity was unsatisfactory.
1.11 : Plasma GST B, in acute liver damage
Beckett et al. (1985a, 1985b) have monitored patients admitted with paracetamol
poisoning to compare plasma levels of GST B,, GST Bz, ALT and AST levels in acute
drug-induced liver damage. In these studies of paracetamol-induced liver damage
Beckett et al. (1985a, 1985b), demonstrated the extreme sensitivity of GST B, or GST
Bz measurements for the detection of acute cellular damage. Seventeen of the 18
patients they studied had abnormal GST concentrations while in contrast only seven
patients had abnormal plasma activities of ALT or AST. Beckett et al. (1989b)
compared the sensitivity of GST B,, F protein and ALT measurements for detection of
liver damage in patients with paracetamol overdose and concluded that GST B, and F
protein offered clear advantages over ALT for detecting minor degrees of acute liver
dysfunction, particularly when only centrilobular damage may be involved.
Other situations where plasma GST concentrations have been measured and
found to be of value include: changes in plasma GST B, after alcohol ingestion (Hayes
et al., 1990), assessing liver damage in neonates who suffered birth asphyxia (Beckett
et al., 1989a) and assessing subclinical liver damage after halothane anaesthesia
(Hussey et al., 1988; Allan et al., 1987).
The data described above all indicate that plasma GST B, concentrations
provide a more sensitive index of hepatic integrity than the aminotransferases.
Sherman et al. (1983a) also concluded that the RIA measurement of 'basic ' GST in
serum was a good prognostic marker in the investigation of viral hepatitis, although
considered that the short half-life of 'basic' GST in plasma weakened its use as a
diagnostic test. Since the AST level had to be elevated by definition in every case of
acute viral hepatitis in the study by Sherman et al. (1983a), they were obviously limited
to finding increased serum levels of 'basic' GST in only as many or in fewer patients.
Possibly if different criteria had been employed to assess the hepatitis 'basic' GST
would have been elevated in the early stages of the disease whereas, AST values may
well still have been within their reference range.
1.12 : Measurement of GST B, in chronic liver disease
In chronic hepatitis markers used to assess disease activity include, aminotransferase
activity, serum globulin concentrations, clinical symptoms and histology. Biopsy
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appearance is the 'gold standard' by which all other tests are compared. Since biopsy
cannot be repeated frequently the aminotransferases are the most commonly used test
for day to day monitoring, even although it is well established that correlation of AST
and ALT with disease activity is poor (Clermont and Chalmers, 1967). Sherman et al.
(1983a) showed that serum GST levels correlated significantly (P<0.01) with the
activity of the hepatitis, as assessed by histology, whereas AST activities showed no
such correlation. Larger studies have never been reported to confirm these findings,
but the data indicates that plasma GST B, measurements may provide an alternative to
liver biopsy in monitoring the progress of chronic active hepatitis and its response to
treatment.
Elevated plasma concentrations of alpha GST have been reported in more than
50% of patients with cirrhosis, in three separate studies (Beckett et al., 1987; Tsuru et
al., 1978; Hirano etal., 1984). Sherman et al. (1983a) however, reported normal 'basic'
GST levels in all 20 patients with cirrhosis, all of whom had raised plasma AST
activities. The data of Beckett et al. (1987) who studied plasma GST B,, GST B2 and
AST levels in 79 alcoholic cirrhotic patients, indicates that measurements of either GST
B1 or GST B2 provides information that is different and additional to, the information
obtained from AST activities alone. Not all patients who had raised AST activities had
raised GST B, concentrations and vice versa. Abnormal results were detected in 53 of
the 79 cirrhotic patients, using both measurements, whereas abnormal AST activities
were only evident in 35 patients. The reason for the discrepancy between GST B, and
AST levels in certain patients in not known, but lobular distribution, length of plasma
half-life and differing sensitivities are probable explanations. It is also possible that
GST synthesis maybe induced or even down-regulated in certain individuals.
Preliminary immunohistochemical work would appear to indicate that in alcoholic
cirrhotic livers the GST pi isoenzyme (not normally expressed in adult hepatocytes) is
expressed (Personal communication Dr. D. Harrison).
Before the advent of effective treatment for hyperthyroidism, hepatobiliary
complications were commonly associated with this disease. As prolonged severe
hyperthyroidism now occurs only rarely, severe hepatobiliary dysfunction associated
with hyperthyroidism is seldom encountered. However, Beckett et al. (1985c) reported
abnormal GST B, concentrations in ten out of 14 hyperthyroid patients at presentation,
whose GST B, levels returned to normal after treatment and concluded that
hyperthyroidism may produce subclinical liver damage in a high proportion of patients.
There is little evidence to suggest that hypothyroidism affects liver function, but
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patients subsequently receive thyroxine replacement therapy and Beckett et al.
(1985c), in eight newly diagnosed hypothyroid patients, demonstrated that these
patients had normal GST B, concentrations at presentation but showed a significant
increase in GST B, levels after thyroxine replacement therapy. Similar though less
consistent changes were seen in the results of AST, yGT and ALP. It was concluded
that hypothyroid patients receiving thyroxine replacement therapy may suffer
subclinical liver damage as a result of their therapy and careful monitoring of thyroid
stimulating hormone was expedient (Gow eta/. 1987). Periodic biochemical
assessment of liver function was also advised.
The mechanism by which thyroxine increases plasma GST B,, although not
known with certainty, is thought to be hepatic damage as opposed to hepatic induction
of the enzyme. Working with a rat model, where the rats were administered high
doses of thyroxine, high levels of plasma YaYa GST (rat equivalent of human GST B,)
were observed with concomitant rises in ALT activity. Thyroxine administration also
produced a significant fall in the hepatic content of YaYa GST (Beckett et al., 1986).
1.13 : Measurement of 'liqandin' in human hepatocellular carcinoma
Ohmi and Arias (1981), showed that 11 out of 15 patients with primary hepatocellular
carcinomas had elevated serum ligandin levels but only three out of 22 patients with
extensive hepatic metastases had elevated serum ligandin levels. Sherman et al.
(1983b) reported elevated levels of 'ligandin' in 17 out of 55 patients diagnosed as
having hepatocellular carcinoma. Both groups reported that hepatic tissue levels of
'ligandin' decreased. The mechanism whereby increased serum 'ligandin'
concentrations occur in primary hepatocellular carcinoma is not known but Ohmi and
Arias (1981) showed by transplanting rat hepatoma cells into nude mice that serum
'ligandin' rises as the tumour grows and concluded that the tumour was the source of
the 'ligandin'. In contrast, Sherman et al. (1983b) demonstrated that, although elevated
serum 'ligandin' concentrations were seen in some patients there was no correlation
with the intensity of tumour staining for 'ligandin' and postulated that serum 'ligandin'
originated from normal adjacent cells damaged by tumour growth.
1.14 : Measurement of 'liqandin' in urine as an indicator of renal damage
After Kirsch et al. (1i,/5) published the paper 'Structural and functional studies of
ligandin, a major renal organic anion-binding protein' (work done with rat tissue), a
number of studies were reported concerning the measurement of ligandin in rat urine
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as a marker for renal damage. Ligandinuria was shown to occur in rats with acute
tubular necrosis (Feinfeld eta!., 1977) and in rats with gentamicin-induced
nephrotoxicity (Feinfeld et a!., 1981).
In 1980, Campbell et al. using immunohistological techniques localized the
expression of 'ligandin' in human kidney to the proximal convoluted tubule and the
thick segment of Henle's loop. These findings have been supported by recent
immunohistochemical work where, alpha GST was reported to be present in the
proximal convoluted tubules with little staining elsewhere, whereas staining for GST pi
was weak in the proximal tubules but strong in the in the distal convoluted tubules and
medullary tubules. Staining for mu-class and microsomal GST was also reported
(Harrison et al., 1989).
Feinfeld et al. (1978) looked for 'ligandin' in perfusates from human kidneys
that were stored prior to transplantation into uraemic patients and reported that
perfusates from 8 kidneys developing post-transplantation acute tubular necrosis had
immunodetectable 'ligandin' levels whereas, the perfusates of 5 kidneys which
functioned immediately where negative for ligandin. This study was confirmed by Cho
et al. (1981) on a larger sample number, the inference being that the appearance of
'ligandin' in the perfusate of a kidney preserved for transplantation could be used to
detect significant ischemic tubular necrosis and predict acute renal failure following
transplantation.
Backman et al. (1989) monitored, by radioimmunoassay, the levels of 'basic'
GST in the urine of 69 recipients of renal allografts. Patients receiving Cyclosporin A
without toxicity or rejection did not express 'basic' GST in their urine whereas the urine
of patients with Cyclosporin A-induced nephrotoxicity contained significant amounts of
GST. However, patients with allograft rejection also showed increased urinary
concentrations of the 'basic' GST although lower values than the Cyclosporin A-
induced nephrotoxicity. Measurement of both GST pi and GST B, in urine may have
given a better differentiation between the two conditions. If the urinary excretion of
GST B, is high as a result of renal injury, and GST pi excretion is low, then it is likely
that damage is restricted to the proximal convoluted tubule and would be due to
Cyclosporin toxicity (Cyclosporin is thought to be primarily a proximal tubule toxin).
The presence of both GST pi and GST B, in urine may reflect more widespread tubular
and even glomerular damage therefore may indicate transplant rejection.
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1.15 : Measurement of GST pi in human tissues
The first measurements of GST pi were probably performed by Scott and Wright (1980)
who measured erythrocyte GST 1-chloro-2,4-dinitrobenzene conjugating activity in a
large number of blood donors. A comparable study was performed by Strange et al.
(1982) who also looked at GST activity in erythrocytes although they first semi-purified
the enzyme to eliminate haemoglobin interference. These studies were performed to
determine the normal expression of GST in erythrocytes, whereas a report by Kilipikari
and Savolainen (1984) found a decrease in erythrocyte GST activity in workers
exposed to hot rubber fumes as compared to normals. Ansari et al. (1987) proposed
measuring GST activity in erythrocytes (GST pi being the predominant GST isoenzyme
present in these cells) as a possible marker for chemical exposure to industrial
toxicants, such as acrolein, propylene oxide, ethylene dibromide and ethylene
dichloride, all of which demonstrated dose-dependent inactivation of human
erythrocyte GST, but no subsequent reports have appeared from these workers.
After GST pi was purified and antibodies became available, the technique of
immunohistochemistry demonstrated that GST pi was elevated in tumour compared to
normal tissue in a number of human tumours originating from colon (Kodate et al.,
1986), stomach (Tsutsumi et al., 1987) and lung (Eimoto et al., 1988). It was therefore
suggested that GST pi may be a useful tumour marker. The first immunoassay for the
quantification of GST pi was an enzyme immunoassay described by Hirano et al.
(1984) for anionic GST but this assay had poor precision and sensitivity. Niitsu et al.
(1989) and Tsuchida et al. (1989) have both recently described immunoassays where
they advocate that the measurement of GST pi levels in serum is a useful tumour
marker for gastrointestinal malignancies. Yoshizaki et al. (1989) described a
radioimmunoassay for erythrocyte acidic GST and used it to measure serum GST pi
concentrations in various haematoiogicai conditions, and suggested that GST pi may be
of use as a clinical marker of increased destruction and/or overproduction of blood
cells such as paroxysmal nocturnal haemoglobinuria and acute lymphocytic leukaemia.
Measurement of GST pi mRNA using a cDNA probe has also been described
(Moscow et al. 1988 & 1989). These workers identified an inverse relationship of GST
pi mRNA levels with oestrogen receptor status in breast cancer tissue and described
elevated levels of GST pi mRNA in tumour as compared to normal tissue in various
cancers.
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1.16 : Measurement of mu-class GST in human tissues
Polymorphism of the mu-class GST, GST /i and GST rp have been examined by three
separate methods; zymogram analysis on starch gels (Board, 1981; Harada et al.,
1987) specific catalytic activity towards trans-stilbene oxide (Seidegard et al., 1986 &
1987) and radioimmunoassay (Hussey et al., 1987a). The subject of GST pi expression
and possible susceptibility to disease states in individuals lacking the enzyme is
discussed more fully in Section 7.
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1.17 Aims of the thesis
The aims of the thesis were to;
1) Purify the GST pi form of cytosolic GST from human placenta, lung and
erythrocyte.
2) Raise antibodies against pure GST pi antigen and determine if GST pi
from placenta, lung and erythrocyte was immunologically identical.
3) Develop a sensitive and specific immunoassay for GST pi
quantification.
4) To use the radioimmunoassay developed for GST pi and the existing
radioimmunoassays for the alpha and mu-class GST to investigate:
a) The clinical utility of GST pi measurements as a tumour marker.
b) Expression of GST isoenzymes in breast cancer cytosols.
c) Expression of GST isoenzymes in adult normal and tumour tissues
and tissues.
d) Expression of GST p in lung cancer patients and age matched
controls.
e) Developmental aspects of GST in normal tissues.
f) Occurrence of GST isoenzymes in lung lavage and bile.
g) Liver damage after general anaesthesia and hypoglycaemia
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Section 2 MATERIALS AND GENERAL METHODS
2.01 : Equipment and Chemical Suppliers
Abbott Diagnostics Division, Maidenhead, Berks., UK
'Thrombotect' blood collection tubes; Platelet Factor 4 RIA kit.
Amersham International, Amersham, Bucks., UK
125l-labelled sodium iodide.
BDH Chemicals Ltd., Poole, Dorset, UK
Acetic acid; acrylamide; 2-amino-2-(hydroxymethyl)propane-1,3-diol(Tris); ammonium
persulphate; brij-35 (30% solution); bromophenol blue; butan-1-ol; calcium chloride;
cellulose microcrystalline; chloramine T; 1 -chloro-2,4-dinitrobenzene; L-cysteine;
dipotassium hydrogen orthophosphate; disodium hydrogen orthophosphate; ethanol;
ethanolamine; ethylenediaminetetra-acetic acid (EDTA); formaldehyde; glycerol;
glycine; hydrochloric acid; hydrogen peroxide; 2-mercaptoethanol; methanol; nitric
acid; NN'-methylenebisacrylamide; orthophosphoric acid; potassium chloride;
potassium dihydrogen orthophosphate; potassium dichromate; potassium hydroxide;
potassium iodide; silver nitrate; sodium acetate; sodium borate; sodium carbonate;
sodium chloride; sodium dihydrogen orthophosphate; sodium dodecyl sulphate;
sodium hydroxide; sucrose; NNN'N'-tetramethyl ethylenediamine (TEMED);
trichloroacetic acid; Whatman No. 1 filter paper.
Bio-Rad Laboratories, Watford, Herts., UK
Nitrocellulose paper; immuno-blot assay kit; Tween-20.
Koch-Light Laboratories Ltd., Colinbrook, Berks., UK
Cumene hydroperoxide.
L.I.P. (Equipment & Services) Ltd., Shipley, West Yorkshire, UK




Millipore (UK) Ltd., Harrow, Middlesex, UK
Ultrafiltration membranes.
Pharmacia Fine Chemicals, Uppsala, Sweden
Isoelectric focusing protein standards.
Randox Laboratories, Crumlin, Northern Ireland
Commercial kits for the estimation of: alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and y-glutamyl transferase (yGT) activities.
Scientific Instruments Centre Ltd., London, UK
Visking tubing for dialysis.
Scottish Antibody Production Unit, Carluke, Lanarkshire, UK
Normal rabbit serum (NRS) and anti-rabbit IgG (donkey) (DARS) precipitating serum.
Sigma Chemical Co. (London) Ltd., Poole, Dorset, UK
Bovine serum albumin (BSA); Coomassie Brilliant Blue (R-250 and G-250); histidine;
Freund's adjuvant (complete and incomplete); gelatin; glutathione reductase;
glutathione (reduced form); nicotinamide adenine dinucleotide phosphate (reduced
form, type X); Pharmalyte pH 3-10; Polybuffer 74; sodium glycocholate; sodium
taurochenodeoxycholate.
2.02 Materials for chromatography
Pharmacia (Laboratory Separation Division), Milton Keynes, Bucks., UK
Mono Q HR 5/5 Fast Protein Liquid Chromatography (FPLC) anion exchange column;
Polybuffer exchanger (PBE) 96.
Sigma Chemical Co., (London) Ltd., Poole, Dorset, UK
Epoxy-activated Sepharose 6B; Sephadex G-25; Sephadex G-100; SP-Sephadex.
2.03 : Materials not obtained from commercial sources
S-Hexylglutathione and S-hexylglutathione-Sepharose 6B affinity matrix was a gift from
Dr.J.D.Hayes. Glutathione-Sepharose 6B affinity matrix was prepared by coupling the
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sulphydryl moiety of glutathione to the epoxy-activated Sepharose 6B as described by
Simons & Vander Jagt (1977).
Antisera raised against human alpha GST, B, and B2 and GST n, as well as the
corresponding standards, for RIA, were provided by Dr J.D. Hayes and Dr G.J. Beckett.
Affinity-purified cytosolic rat lung GST was also provided by Dr J.D. Hayes. Purified rat
and mouse Yf GST, used for cross-reactivity experiments, was a gift from Dr L.M.
McLellan. Purified GST4 from human heart tissue was a gift from Dr R.C. Strange.
2.04 : Animals
New Zealand white rabbits, used for raising antisera, were obtained from Charles River
Breeding Laboratories, UK.
2.05 : Protein determination
Protein concentrations, in fraction samples eluted from chromatography columns, were
calculated from the extinction values at 280 nm. An absorbance reading of 1.0 was
taken to represent a protein concentration of 1 g/L.
All other protein estimations were carried out utilizing the dye-binding technique
of Bradford (1976) adapted for use on a Cobas Fara (Roche Diagnostics, Welwyn
Garden City, UK) centrifugal analyser. Working Coomassie Brilliant Blue G-250 was
prepared as described by Bradford (1976) although it was filtered, before use, through
Whatman grade 1 filter paper. Reagent (256 fjI) was added to each cuvette and
incubated at 37 °C for 100 s with an initial absorbance reading (595 nm) taken at 95 s,
after the addition of 25 /ul of sample plus 50 /j| of distilled water as diluent, the cuvettes
were incubated at 37 °C for a further 180 s, when a final absorbance reading was
taken at 595 nm. A standard curve, using bovine serum albumin, was constructed
from 0 to 100 mg/l. The difference between the final and initial absorbance points
was calculated and a standard curve was plotted. The protein concentration of
unknown samples were interpolated from this curve. Samples with protein
concentrations greater than 100 mg/l were diluted in distilled water. The within batch
CV was found to be <2% and the between bath CV was <5%.
2.06 : Sodium determination
Sodium concentrations, in the Fast Protein Liquid Chromatography (FPLC) column
eluates, were measured by flame photometry using an IL543 photometer
(Instrumentation Laboratory (UK) Ltd., Warrington, Cheshire, UK).
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2.07 : GST activity
Assays for cytosolic GST activity with 1-chloro-2,4-dinitrobenzene (CDNB) as substrate
were carried on the Cobas Fara centrifugal analyser essentially as described by Hayes
& Clarkson (1982). All assays were carried out at 37 °C and a non-enzymic rate
determined which was subtracted from the rates observed in samples. Up to 29
samples were simultaneously pre-incubated with reduced GSH and the reactions
started with the addition of CDNB. The final substrate concentrations were 2 mmol
and 1 mmol for GSH and CDNB respectively in a reaction volume of 250 pi containing
0.1 mol sodium phosphate buffer pH 6.5. The reactions were monitored by initial
measurement of absorbance at 340 nm, 10 s after mixing, followed by 7 further
absorbance measurements at 5 s intervals. Reaction rates were determined by an
integral kinetic data analysis program, which performed linear regression analysis on
the 8 absorbance readings from each cuvette. The AA/min was multiplied by a
conversion factor, which depended on the sample volume, and the results expressed
as AA/min/mL of sample. The assay was linear up to levels of 300 AA/min/mL,
samples with enzyme activity >300 were diluted in distilled water and re-assayed. The
within batch CV was <4% and between batch CV <10%. All samples were performed
in duplicate.
2.08 : Glutathione Peroxidase Activity
Measurement of selenium dependent (sGPX) and independent (tGPX) glutathione
peroxidase utilised an adaptation of the Paglia and Valentine (1967) method for use on
a Cobas Fara centrifugal analyser. The final concentration of the peroxides was 0.6
mmol/L for hydrogen peroxide and 1.2 mmol/L for cumene hydroperoxide. The assay
solution contained 60 mmol/L Tris/HCI buffer pH 7.6 (21 °C), 0.12 mmol/L EDTA, 1
mmol/L NaN3, 0.33 mmol/L NADPH, 1.3 mmol/L reduced glutathione and 1.3 units/mL
glutathione reductase. After a 5 minute incubation (20 pL sample: 50 pL HzO wash:
260 pL assay solution) the reaction was started with the addition of peroxide (5 pL). A
water blank value was subtracted for each determination. The rate of the reaction was
determined by following the decrease in absorbance at 340nm at 37 °C. Results were
expressed as umol of NADPH oxidised/min/L. The within-batch CV was <4% and the
between batch CV was <10%. All samples were performed in duplicate.
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2.09 : SDS/Polvacrvlamide-qel electrophoresis (SDS/PAGE)
SDS/PAGE was carried out in slab gels (0.1 cm x 16.5 cm x 18 cm) at room
temperature using a PROTEAN II electrophoresis system (Bio-Rad Laboratories Ltd.,
Watford, Herts., UK) in the presence of 1% SDS (w/v) and employing the buffer system
described by Laemmli (1970). The "resolving gel" was 14 cm long, of 12% (w/v)
polyacrylamide and 2.6% (w/v) NN'-methylenebisacrylamide in 375 mmol/L Tris/HCI
buffer pH 8.8. The "stacking gel" was 2.5 cm long and comprised 3% (w/v)
polyacrylamide in a 125 mmol/L Tris/HCI buffer pH 6.8 and was formed on top of the
"resolving gel".
Protein samples were prepared for electrophoresis by heating at 90 °C for 10
min in an aqueous solution of: SDS, 35 mmol/L; glycerol, 1.4 mmol/L; 2-
mercaptoethanol, 0.3 mmol/L and bromophenol blue, 15 mmol/L. The desired volume
of these "boiling mixes" were applied to wells in the "stacking gel" and electrophoresis
was carried out, at 50 mA per gel , through the "stacking gel" and then at 25 mA per
gel, through the "resolving gel". The current was stopped when the bromophenol blue
marker reached within 0.5 cm from the end of the gel. The gel was stained either with
a 0.2% (w/v) Coomassie Brilliant Blue R in water/methanol/acetic acid (50:50:7, by vol.)
and destained in several changes of water/methanol/acetic acid (88:5:7 by vol.) or by
the highly sensitive silver stain technique as described by Switzer et al. (1979).
The silver stain technique involved soaking the gel for at least 1 h in a
water/methanol/acetic acid (38:50:12, by vol.) solution before oxidising for 15 min with
3.4 mmol/L potassium dichromate containing 3.2 mmol/L nitric acid. The gel was then
washed for 10 min in distilled water before being placed in the silver stain consisting of
12 mmol/L silver nitrate for 20 min, after a brief rinse in distilled water the gel was
placed in the developing solution consisting of 6.7 mmol/L formaldehyde in 280
mmol/L sodium carbonate for 5-10 min and the reaction stopped by the addition 3%
(w/v) acetic acid solution.
Molecular mass values for subunits of cytosolic GST were estimated by using
GST mixtures from rat, where subunit Mr values had previously established (Hayes &
Mantle, 1986c).
2.10 : Isoelectric focusing in polvacrvlamide-qels
Isoelectric focusing (IEF) was performed in 5% (w/v) polyacrylamide slab gels (24 cm x
11.5 cm x 0.2 cm), containing 10% glycerol (v/v) and 5% Carrier Ampholine mixture
(v/v) pH range 3-10. Electrofocusing was carried out on a LKB 2117 Multiphor using a
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LKB 2103 power supply as described by the manufacturer (LKB-Produkter AB,
Bromma, Sweden). The electrode solutions were 1 mol H3P04 (anode) and 1 mol
NaOH (cathode). Samples (25 pg protein) were applied to strips (1 cm x 1 cm) of
Whatman No. 1 paper placed 3 cm from the cathode electrode. Pharmacia IEF
calibration markers were included on all gels and comprised; trypsinogen, pi 9.30;
lentil lectin, pi, 8.65, 8.45 and 8.15; myoglobin, pi 7.35 and 6.85; human carbonic
anhydrase B, pi 6.55; bovine carbonic anhydrase B, pi 5.85; /S-lactoglobulin A, pi
5.20; soybean trypsin inhibitor, pi 4.55 and amyloglucosidase pi 3.50.
The focusing was performed at a constant power (25W) for 3 h, the sample
applicators being removed after 1 h. The gels were fixed in an aqueous solution of
sulphosalicylic acid (3.5%, w/v) and trichloroacetic acid (11.5%, w/v) for 30 min before
washing for 30 min in destaining solution composed of, water/ethanol/acetic acid
(67:25:8 by vol.). A 0.12% (w/v) Coomassie Brilliant Blue R solution was employed to
stain the gel at 60 °C for 10 min. Destaining was achieved using several changes of
destaining solution.
2.11 : Western blotting
Western blotting was performed by the method of Towbin et al. (1979), as described
by Hayes & Mantle (1986a). Proteins were subject to SDS/PAGE and following
electrophoresis, the gels washed in 25 mmol/L Tris containing 192 mmol/L glycine, pH
8.3 at 20 °C, for 20 to 30 min before being transferred to nitrocellulose paper. Transfer
was carried out in the same buffer as above, using a Bio-Rad Trans-Blot cell and Bio-
Rad model 250/2.5 power supply (Bio-Rad Laboratories, Watford, Herts., UK). The
electrophoretic transfer of polypeptides to nitrocellulose paper was performed at 0.25 A
for 4 h, at 10 °C. The paper was then soaked in a blocking solution composed of
gelatin 3% (w/v) in 20 mmol/L Tris/HCI, pH 7.5, containing 500 mmol/L NaCI, for 16 h
at 20 °C, to reduce the non-specific binding of antibody to the nitrocellulose. After
blocking with gelatin, the nitrocellulose papers were incubated for 3 h at 20 °C with the
first antibody which was diluted 1:3000 in 200 mL of 1% (w/v) gelatin in 20 mmol/L
Tris/HCI buffer, pH 7.5, containing 500 mmol/L NaCI and 0.05% (v/v) Tween-20.
Following washing of the papers with distilled water and buffer, visualisation of the
polypeptides which cross-reacted with the specific first antibody was achieved using a
second (goat anti-rabbit IgG) antibody labelled with horseradish-peroxidase (Bio-Rad
immunoblot assay kit), according to the manufacturers instructions (Bio-Rad
Laboratories, Watford, Herts., UK). A portion of the immunogen for the first antibody
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was run in parallel with test proteins, to act as standard and control.
2.12 : Preparation of 125l GST pi. B,. Bo, and u
The iodination procedure was identical for all four proteins. Protein (10 pL; 5 fjg) and
potassium phosphate buffer 0.25 mol/L pH 7.4 at 20 °C (10 pL) were added to a glass
test tube followed by 125l-sodium iodide (5 pL; 18.5 MBq) and chloramine T (10 pL; 16
pg). After 15 s cysteine (100 pL; 56 pg), potassium iodide (10 pg; 100 pg) and diluent
(250 pL) were added to stop the reaction. The diluent consisted of 25 mmol/L
potassium phosphate, pH 7.5 containing bovine serum albumin (1 g/L) and sodium
azide (0.2 g/L). The contents of the tube were then transferred to a gel filtration
column consisting of 1 cm x 12 cm bead of Sephadex G-25. The column had
previously been equilibrated with diluent. The column was eluted with diluent (0.5
mL/min) and fractions containing iodinated protein pooled and used for the
radioimmunoassay.
2.13 : Preparation of pre-precipitated DARS/NRS second antibody
This was prepared by mixing DARS (20 mL) with NRS (1.5 mL) and allowing
precipitation to take place overnight at room temperature. After centrifugation (10 min
1500 x g) the supernatant was discarded, the precipitate washed twice with 20 mL
assay diluent consisting of 25 mmol/L sodium phosphate, pH 7.5, bovine serum
albumin (1 g/L) and sodium azide (0.2 g/L), and re-suspended in 125 mL assay
diluent. This solution was stored at 4 °C.
2.14 : Radioimmunoassay of GST B,, B, and u.
These assays were performed essentially as described by Beckett & Hayes (1984) and
Hussey et at. (1987). The assay protocols were identical for all 3 assays. All test
reagents and specimens were brought to room temperature before beginning the test.
Tubes were labelled for the performance of the test as follows:
a) Tubes 1 & 2, Total Count Tubes, for the determination of total radioactivity.
b) Tubes 3 & 4, Nonspecific Binding (NSB).
c) Tubes 5 to 20, for the appropriate standards in duplicate.
d) Tubes 21, etc. for the unknown specimens in duplicate.
Buffer, standard or sample (100 ^L) was incubated with antiserum (100 pL), at 4 °C, for
24 h before tracer (100 /jL; 40 000 cpm) was added to all tubes. The tubes were
incubated for 24 h, at 4 °C, when DARS (100 nL) was added to all tubes, except 1 & 2,
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and a further 1 h incubation at room temperature undertaken. A wash solution (2 mL;
0.05% aqueous Brij 35) was added to all tubes, except 1 & 2, and the tubes
centrifuged for 30 min (4 °C, 3000 x g). The supernatant was decanted and the
precipitate counted in a LKB 1261 Multigamma gamma counter and the data
processing performed using the LKB 1224-Ria Calc. LM RIA evaluation program (LKB-
Products, Bromma, Sweden).
Standards of GST were made up in assay diluent after the protein
concentration had been determined using the method of Bradford (1976). Final, first
antibody titres for GST B,, B2, and /j were 1 in 90 000, 1 in 45 000 and 1 in 3 000
respectively.
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Section 3 PURIFICATION AND CHARACTERISATION OF GST pi
3.01 : Purification of GST pi from human placenta
Normal 40-wk full-term placentas obtained within 8 h of delivery were used and all
procedures were carried out either on ice or at 4 °C. The placenta (about 600g) was
cut into 4 cm3 pieces and, after the removal of the amniotic membrane, washed with 2
L of 0.25 mol/L sucrose solution to remove excess blood. The washed placenta (about
500 g) was homogenised with 1 litre 20 mmol/L sodium phosphate buffer pH 6.5 and
centrifuged at 15 000 x g for 2 h. The supernatant (placental cytosol) was then
dialysed for 24 h against two changes, each of 5 L of 20 mmol/L sodium phosphate
buffer, pH 6.5. The cytosol was then applied to a 4.5 cm x 80 cm SP-Sephadex cation
exchange column previously equilibrated with 20 mmol/L sodium phosphate buffer, pH
6.5. The flow-rate was 36 mL/h and 12 mL fractions were collected.
Glutathione S-transferase activity that was not retained by the column was
combined (Pool 1) and applied immediately to an S-hexylglutathione-Sepharose 6B
affinity column (1.6 cm x 17 cm). The column was washed overnight (24 mL/h) with 20
mmol/L Tris/HCI buffer, pH 7.8, containing 200 mmol/L NaCI. The GST enzymes were
then eluted with 5 mmol/L S-hexylglutathione in the running buffer and 5 mL fractions
were collected. The GST-containing fractions were combined (Pool 2) and dialysed
against two changes, each of 2 L, of 25 mmol/L histidine/HCI buffer, pH 6.2, for 24 h.
The dialysed protein was subject to chromatofocusing which was performed
using a 1.6 cm x 30 cm column of PBE 94 that was previously equilibrated with 25
mmol/L histidine/HCI buffer, pH 6.2; polybuffer 74 diluted 8-fold with distilled water and
adjusted to pH 4.0 with HCI, was used as the elution buffer. Pool 2 was not loaded on
to the chromatofocusing column until after 10 mL elution buffer had been applied, and
the column was then eluted at 24 mL/h; 8 mL fractions were collected.
The peak of GST activity, which eluted in the region, pH 4.9-4.6, was combined (Pool
3) and re-applied to a S-hexylglutathione affinity column to remove polybuffer.
Following this second affinity chromatography step the GST was dialysed against two
changes, each of 2 L, of 20 mmol/L sodium phosphate buffer, pH 6.5, and was stored
at -70 °C until required.
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3.02 : Purification of GST pi from human lung
Pieces of normal human lung were obtained within 8 h of death from the post-mortem
suite. The GST pi from human lung was purified using a scheme identical to the
human placenta purification described above.
3.03 : Purification of GST pi from human erythrocytes
Packed erythrocytes (250 ml.) <6 h old, were obtained from whole blood sent to the
Department of Clinical Chemistry for biochemical analysis. The blood was centrifuged
at 2 500 x g for 15 min, and the plasma removed. The packed erythrocytes were
washed twice in 20 mmol/L sodium phosphate buffer, pH 6.5, containing 110 mmol/L
NaCI and filtered through cotton wool to minimise leucocyte contamination. The
erythrocytes were harvested from the buffer by centrifugation at 2 500 x g and lysed by
adding an equal volume of 20 mmol/L sodium phosphate buffer pH 6.5 (4 °C). The
purification procedure of the erythrocyte GST was essentially the same as for the
placental preparation except that the final affinity chromatography step was carried out
using a glutathione affinity column (Simons and Vander Jagt, 1977) instead of a S-
hexylglutathione affinity column.
The peak of GST activity, which eluted of the chromatofocusing column, in the
region, pH 4.9-4.6, was combined and applied to a glutathione affinity column (1.6 cm
x 17 cm) that had been equilibrated with 22 mmol/L sodium phosphate buffer, pH 7.0.
The column was washed with the equilibration buffer overnight and the column
developed with 50 mmol/L Tris/HCI (pH 9.6 at 4 °C) containing 5 mmol/L reduced
glutathione. The peak of GST activity was dialysed against two changes, each of 2 L,
of 20 mmol/L sodium phosphate buffer, pH 6.5, and stored at -70 °C until required.
3.04 : SDS/PAGE and IEF of purified GST pi
These techniques were carried out as described in the methods section (2.09 and
2.10). Both gels were stained using Coomassie Brilliant Blue. Approximately 5 fjg of
GST was applied to the SDS/page gel whereas 25 fjg was applied to the IEF gel.
Isoelectic points (pi) of the proteins were established by measuring the distance the
standards had migrated from the cathode, plotting a graph of pi versus distance
travelled and reading off the pi value for the unknowns.
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3.05 : Results of GST pi Purification
Column profiles from each stage in the purification scheme for the placental
preparation are shown in figures 3a-d. The column profiles for the lung and
erythrocyte preparations were essentially the same as those illustrated for the placenta.
The amount of pure GST pi recovered from placenta, lung and erythrocytes is shown
in table 3a. The result of SDS/PAGE analysis is shown in figure 3e, all three pure GST
proteins running as a single band with an apparent Mr weight of 24 800, when
compared against rat lung affinity purified GST standards. The graph obtained from
the standard proteins run during isoelectric focusing is illustrated in figure 3f, each
GST was found to migrate as a single band with a pi of 4.75.
TABLE 3a: Comparison of human GST pi levels recovered from each tissue.
Amount of Amount of Yield of
Starting pure GST GST
material recovered (% x 103)
Placenta 500 g 26.0 mg 5.2
Lung 734 g 16.1 mg 2.2























Figure 3a: Elution profile of placental GST from an SP-Sephadex cation exchange
column. Placental cytosol was applied to the 4.5 cm x 80 cm column
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Figure 3b: Elution profile from the initial S-hexylglutathione affinity column step.




Figure 3c: Elution profile from the chromatofocusing column. The peak of GST























Figure 3d: Elution profile from the second S-hexylglutathione affinity column step.
Protein concentration and CDNB activity are represented by • and A
respectively.
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Figure 3e: Electrophoretic properties of human GST pi compared with a
preparation from rat lung. The GST samples were analysed by
SDS/PAGE as follows: 1, rat lung Yf (Mr 24 800), Yb (Mr 26 300) and
Yc (Mr 27 500) subunits; 2, human placenta; 3, human lung;
4, human erythrocyte; 5,rat lung Yf, Yb and Yc subunits.
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Figure 3f: Isoelectric focusing results. Illustrated are the relative distance each
reference protein and GST migrated from the cathode. The distance
the GST isoenzymes migrated is marked with a A.
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3.06 : Discussion
The purification scheme developed for GST pi gave a high yield of homogeneous
protein, and was found to be applicable to at least three different tissues that are rich
in GST pi, placenta, iung and erythrocyte. The reason the glutathione-Sepharose 6B
affinity gel was employed, as the final step, for erythrocytes was that initially the
preparation was found to be contaminated with a slightly higher Mr weight polypeptide,
if a S-hexyiglutathione-Sepharose 6B affinity column was used. This band was thought
not to be a GST, but possibly carbonic anhydrase, which has an acidic isoelectric
point, a subunit Mr weight of about 29 000, known to be present in erythrocytes and
reported as binding to S-hexylglutathione 6B affinity gel (Personal communication, B.
Mannervik to J.D. Hayes).
The yield of GST pi obtained was about 5-fold greater than that reported for
previous methods (Guthenberg eta!., 1979; Partridge etai, 1984; Marcus eta/., 1978).
Koskelo et al. (1981) described a purification scheme that resulted in the isolation of
GST from human lung in amounts twice those reported here, but their preparations
were only 90% pure when analysed by polyacrylamide gradient gel electrophoresis.
In this investigation, subunit molecular mass and the isoelectric point of the
three GST enzymes isolated were found to be identical. Previous comparisons between
the physicochemical and immunological properties of the pi class GST found in
placenta, lung, erythrocyte, spleen and kidney has shown that these enzymes are
closely related (Koskelo, 1983). However, using agarose gel electrophoresis (Suzuki et
al., 1987), GST pi from erythrocytes was found to have a mobility which differs from
GST pi purified from other tissues. Similarly, during SDS/PAGE, Vander Jagt et al.
(1985) showed that there was a molecular weight difference between placental (Mr 25
200) and erythrocyte (Mr 24 800) subunits of the GST pi. It has been suggested that
these differences may be due to tissue-specific post-translational modification (Suzuki
et al., 1987). Together with the immunological data presented in Section 4 this data
supports the widely held view that GST pi from placenta, lung and erythrocytes are
genetically identical.
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Section 4 DEVELOPMENT OF A GST pi RADIOIMMUNOASSAY
AND PLASMA MEASUREMENTS
4.01 : Preparation of antisera
Antisera were raised against human GST pi purified from lung and placenta. Purified
GST (0.1 mg/mL) was emulsified with an equal volume of Freund's complete adjuvant.
Freund's adjuvant (5 mL) was placed in a 25 mL universal on ice and an equal amount
of protein solution, added drop-wise, with thorough mixing using a polytron
homogeniser (Kinematica, Switzerland). The protein-containing emulsions were
injected subcutaneously, at multiple sites, into female New Zealand White Rabbits (2
mL) , so that each rabbit received 100 pg of purified GST. Four rabbits were
immunised with GST pi obtained from placenta and 4 rabbits with lung GST pi. After 6
weeks, each rabbit received a booster injection of immunogen (100 pg) prepared as
described above in Freund's incomplete adjuvant. After a further two weeks, the
animals were anaesthetized and blood recovered by cardiac puncture. The blood
was allowed to clot before centrifugation at 3000 x g for 30 min, the serum removed
and stored at -20 °C.
4.02 : Preparation of1251 GST pi
lodination of purified GST was performed as described in section 2.14. For iodination
it was important to use purified GST pi that had been stored at -70 °C for less than 6
months. Purified GST pi that had been stored for longer than 6 months required re-
purification as follows: Purified GST pi (2 mg/5 mL) from human placenta, in 20
mmol/L Tris/HCI buffer (pH 7.4 at 21 °C) containing 0.015% mercaptoethanol, was
applied at 0.5 mL7min to a Mono Q, Fast Protein Liquid Chromatography (FPLC)
column previously equilibrated with the same buffer. The column was developed with
a gradient of 0-150 mmol/L NaCI in the equilibration buffer. Fractions (0.5 mL) were
analysed for GST activity, protein concentration and sodium concentration. The
appropriate fractions were pooled and dialysed (24 h at 4 °C) against 2x1 L, 50
mmol/L sodium phosphate buffer pH 7.4 and stored
at -80 °C.
Figure 4a. shows the elution pattern obtained from the FPLC anion-exchange
column. The second peak that eluted was used for iodination. Glutathione S-
transferase activity using CDNB as substrate co-eluttd with both protein peaks.
Purified GST pi from the same preparation of human placenta (stored at -80 °C) has
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been subject to re-purification on anion-exchange FPLC on three occasions, each re-















Figure 4a, Mono Q anion exchange column profile of GST pi. Protein
concentration ( • ) was measured using the method of Bradford
(1976). GST activity ( O ) was measured using CDNB as substrate.
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Figure 4b illustrates a typical sephadex G-25 column profile obtained after the
iodination of GST pi. The tracer in the first peak bound strongly to the GST pi antisera
whereas, the second peak eluted in the salt volume was the free iodide peak and
showed no binding to antisera. In this particular example, it was calculated that 33%
incorporation of 125l was achieved, and that the specific activity of the labelled protein
was 1.2 MBq/pg. Fraction numbers 4 and 5, (estimated as containing 2.8 /ug of
labelled protein) were combined and stored at 4 °C until required, lodinated protein
was used within six weeks of preparation, thereafter precision became unsatisfactory
due to decreased binding in the presence of no antigen, resulting in a loss of slope on
the standard curve.
Fraction Number
Figure 4b. Elution profile of iodinated GST pi after purification
using Sephadex G-25.
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4.03 : Assessment of antibody titre
A constant amount of the labelled antigen, 125I-GST pi (100 pL: 40 000 cpm) was
incubated with doubling dilutions of each antiserum (100 pL) and 100 pL of assay
diluent, in triplicate and incubated for 24 h at 4 °C. The distribution of radioactivity
bound to antibody and free fractions was determined after separation of bound and
free fractions using pre-precipitated donkey anti-rabbit serum (DARS) (Section 2.14).
Pre-precipitated DARS (100 pL) was added to each tube and incubated with shaking,
at 21 °C for 1 h. A wash solution (2 mL; 0.05% aqueous Brij 35) was added to all
tubes except the total counts, and the tubes centrifuged for 30 min (4 °C, 3000 x g).
The supernatant was decanted and the precipitate counted in a LKB multigamma
counter. The tracer bound to antibody, for each dilution of antibody, was plotted and
the titre expressed as the amount of antisera required to bind 50% of tracer. Figure 4c.
illustrates the different antibody dilution curves obtained for the 8 sera under
investigation. The two antisera with the highest titres (Nos. 7 & 8),(1 in 3 000 initial
dilution) were investigated further.
In order to assess the avidity of antisera 7 & 8 that showed the best titre,
duplicate antibody dilution curves were set up as above, but in one curve the assay
diluent was replaced by 100 pL of 10 pg/L GST pi standard. The difference in binding
in the presence of diluent or 10 pg/L GST pi at each dilution of antisera was
calculated. Figures 4d i & ii. illustrates the antiserum dilution curves for antisera
numbers 7 & 8 with and without GST pi. As can be seen from the figures both
antisera demonstrated equal separation between the two curves, with maximal
differences in binding occurring at an initial antibody dilution of 1 in 1000. Antibody
titres for each antisera are shown in table 4a.
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1:100 1:300 1:1000 1:5000
Antiserum Dilution
Figure 4c. Antiserum dilution curves using doubling dilutions of sera from 8
rabbits. Symbols *,x,aando correspond to rabbit numbers 1
to 8 respectively.
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Antiserum Dilution Antiserum Dilution
Figure 4d,i. Antisera dilution curves with (A) and without (A) 10 /vg/L GST pi for
antiserum number 7.
Figure 4d,ii. Antisera dilution curves with (O) and without (•) 10 /ig/L GST pi for
antiserum number 8.
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4.04 : Preparation and storage of GST pi standards
The protein concentration in the stock solution of GST pi was determined by the
method of Bradford (1976) and working standards were prepared and stored at
-20 °C in 0.5 mL portions. Initially, (1000, 500, 250, 100, 50, 25, 10, 5 fjg/\) were
prepared in assay diluent, which contained 1 g/L bovine serum albumin to reduce
adsorption losses and stabilise the GST pi. Standards were prepared from GST pi
purified from either placenta, lung and erythrocytes.
Latterly, when it became apparent that heat treatment of serum could destroy
GST pi immuno-activity, pooled serum, obtained from blood donors, was heated at
55 °C for 30 min and used in the preparation of GST pi standards.
Heat treatment of serum: Purified GST pi from placenta was added to pooled human
serum (obtained from blood donors) to give a total concentration of 125 /jg/L. Portions
were then heated at 25, 31, 36, 41, 49 and 55 °C in a water bath for 30 min, cooled
and stored at -20 °C until the GST pi concentration could be measured by RIA. Figure
4e illustrates the GST pi concentration, as assessed by RIA, in serum that had been
heated for 30 min at various temperatures. On the basis of this result, pooled serum
was heated at 55 °C for 30 min and used in the preparation of GST pi standards for
Temperature °C
Figure 4e. GST P' (mean + SD) concentrations in sera heated at various
temperatures for 30 min.
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4.05 : Assessment of antibody specificity
Radioimmunoassay is based on competition between the antigenic determinants of the
labelled and unlabelled antigen in the presence of a limited number of specific
antibody binding sites. Other substances that have similar structures to the antigen
will also compete with the labelled and unlabelled antigen for the antibody binding
sites and therefore cross-react with the antisera.
The cross-reactivity of three GST pi preparations obtained from placenta, lung
or erythrocytes were determined as follows. Standard curves were set up in duplicate
for each antigen. This was done for each of the 8 antisera under investigation at titres
established from the antibody dilution curves. The labelled antigen in all cases was
GST pi purified from placenta.
Figure 4f illustrates the example of antiserum number 8, when it was tested
against the GST pi standards purified from the three different tissues, placenta, lung
and erythrocyte. No significant difference could be seen in any of the dose response
curves. This was also the result with the other 7 antisera tested.
GST pi concentration (yug/l)
Figure 4f. A comparison of the dose response curves, with antiserum No. 8,
against GST pi standards purified from placenta (•), lung (X) and
erythrocyte (A). In all experiments 125I-GST pi was placental in origin.
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Cross-reactivity was assessed using the method of Abraham (1969) for human
B,, B2, p, ip, rat Yf and mouse Yf GST for antisera numbers 7 and 8. In each case the
maximum GST concentration assayed was 2 mg/L, again labelled placental GST pi
was employed. Table 4a. illustrates the various titres and cross-reactivity
characteristics of the various antibodies produced.
Table 4a: Titres and cross-reactivity of antisera raised to GST pi. Antisera titres
are defined as the final dilution of antisera required to bind 50% of
125l-labelled GST pi. The relative cross-reactivities are defined as the
quantity of protein which was required to produce 50% displacement of
bound ligand when compared with the original immunogen.
Antiserum 12345678
Immunogen Lung Lung Lung Lung Placenta Placenta Placenta Placenta
Titre (initial) 1:300 1:350 1:600 1:1200 1:350 1:1200 1:3000 1:3000
GST RELATIVE CROSS-REACTIVITY (%)
GST pi (placenta) 100 100 100 100 100 100 100 100
GST pi (lung) 100 100 100 100 100 100 100 100
GST pi (erythrocyte) 100 100 100 100 100 100 100 100
GST Bj nd nd nd nd nd nd <0.1 <0.1
GSTB2 nd nd nd nd nd nd <0.1 <0.1
GST p. nd nd nd nd nd nd <0.1 <0.1
GST nd nd nd nd nd nd <0.1 <0.1
RAT GST Yf nd nd nd nd nd nd <0.5 <0.5
MOUSE GST Yf nd nd nd nd nd nd <0.5 <0.5
nd, represents not determined.
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4.06 : The effect of delayed tracer addition
The sensitivity of a RIA can be increased if addition of the tracer is delayed for 24 h
after antigen and antibody have been incubated. This has been well described for RIA
for GST B1 and B2 (Beckett and Hayes, 1984). Hussey et al (1987a) also employed
this technique for increasing sensitivity in the RIA of GST p. The use of delayed tracer
addition was therefore investigated for the GST pi assay.
Two assays were set up in parallel, in one the antibody (100 pL), standard (100
/jL) and tracer (12SI-GST pi: 100 pL) were added concurrently and the tubes incubated
for 48 h before the separation of bound and free 125I-GST pi by the addition of pre-
precipitated DARS. In the other, antibody and standard were incubated for 24 h prior to
the addition of tracer and a further incubation of 24 h before pre-precipitate DARS was
added. Figure 4g illustrates the two standard curves obtained from the above
experiment. The minimum detection limit, as defined by the lowest GST pi
concentration giving a coefficient of variation (CV) of below 22.5%, was lowered from




















GST pi concentration (ijg/L)
hgure 4g. The effect of delayed tracer addition on the calibration curves for the
GST pi radioimmunoassay. Assay («) used no delayed tracer
addition whereas, assay (Q) employed delayed tracer addition.
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4.07 : GST pi radioimmunoassay protocol
The final protocol chosen for the GST pi RIA was as follows. Antibody 8 (raised from
GST pi purified from placenta) was employed at an initial dilution of 1:1000. The
antisera (100 /jL) was incubated with 100 pL of standard or unknown for 24 h (4°C)
after which 100 /jL (40 000 cpm) of tracer was added. After a further 24 h incubation (4
°C) 100 /iL of pre-precipitate of DARS was added and the tubes shaken for 1 h at room
temperature. The wash solution was then added (1.5 mL) and the tubes centrifuged
for 30 min (4 °C, 3000 x g). The supernatant was carefully decanted and the
radioactivity bound to the precipitate counted in a LKB 1261 Multigamma counter and
the data processing performed using the LKB 1224-RIA Calc. LM evaluation program
(LKB-Products, Bromma, Sweden).
4.08 : Precision of the GST pi radioimmunoassay
Three in-house plasma pools were prepared by collecting previously analysed samples
and pooling groups of samples with similar GST pi levels. In order to obtain the high
pool value a number of grossly haemolysed samples were included (approximately
20%). Pooled samples were mixed thoroughly, centrifuged at 3 000 x g for 30 min
at 4 °C, then filtered through Whatman No. 1 filter paper before being portioned in
0.5 mL aliquots and stored at -20 °C, ready for analysis.
The mean within-assay precision, calculated from standard curves in 8
consecutive assays, is shown in figure 4h. The between-assay precision was
determined using the in-house plasma pools. The precision was calculated from 17,
30 and 30 assays, for the low, medium and high pools respectively (table 4b).
Table 4b: Between-batch variation for 3 pools run in consecutive assays for
GST pi.
n mean SD CV
POOL 1 17 31 2.9 9.4
POOL 2 30 70 6.6 9.5
POOL 3 30 250 11.9 4.8
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Figure 4h: An example of a standard curve and the mean inter-assay precision
profile (± SD) for 8 consecutive human GST pi assays.
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4.09 Precautions required for the collection of Patient Plasma
Effect of haemolysis on GST pi concentrations in plasma: Bloods (n = 14) were
obtained from the Department of Clinical Chemistry's reception area, where they had
been sent for routine biochemical analysis. The blood, collected into a lithium heparin
tube, was divided into two portions, one was centrifuged at 3000 x g immediately for
15 min and the plasma stored at -20 °C until analysis, the other was stored at -20 °C
without centrifugation and only centrifuged (3000 x g for 15 min) before analysis. The
freezing and thawing of the whole blood caused gross haemolysis. The mean ± SD
for the clear plasma was 43 ± 17 pg/L and the haemolysed sample 550 ± 405 pg/L.
Effect of delay in centrifuging blood samples on plasma levels of GST pi: In order to
investigate the effects of any delay in separation of cells from plasma blood (40 ml.)
was collected without venous stasis from eight healthy volunteers into heparinised
tubes. The blood was portioned and left either at 4 °C or room temperature for 0, 1,2,
4, 6, 8, 24 and 48 h before being centrifuged at 3000 x g for 30 min at room
temperature. The plasma was removed immediately after centrifugation and stored at -
20 °C until analysis. Plasma samples showing signs of haemolysis were not assayed.
The GST pi concentrations were measured by the RIA and the mean (± SD) results are
shown in figure 4i. There was a significant (P<0.01; Student's f-test) increase in GST
pi after 1 h; this was much larger for specimens kept at room temperature than at 4°C.
After 1 h at room temperature there was no further significant increase in GST pi over
the next 24 h. Although at 4 °C no significant rise was recorded over the first hour a
significant increase (P<0.05) was recorded within 2 h. This rise in GST pi
concentration was not as marked as that seen at room temperature (figure 4i.)
although after 24 h, in both blood stored at room temperature and 4 °C, GST pi
concentrations had increased 5 to 6-fold from its initial level. Further significant
increases in GST pi concentrations were seen in the next 24 h at either temperature.
The initial (within the first 24 h) rise was thought be caused by the release of
platelet GST pi and is discussed further. The secondary rise occurring from 24 h is
probably due to leakage of GST pi from the erythrocytes.
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Figure 4i: Effect of delayed centrifugation of blood samples on plasma levels of
GST pi. Samples stored at 4 °C before centrifugation (X). Samples
stored at room temperature before centrifugation (O).
61
Effect of centrifugal force on plasma GST pi levels: Blood (30 mL) was taken without
venous stasis from four healthy volunteers into heparinised tubes. Each specimen was
divided into portions and centrifuged within 2 min at 150, 260, 580, 1040 and 2300 x g
for 30 min at room temperature. Following centrifugation the plasma was separately
immediately and stored at -20 °C until analysis. The mean (± SD) plasma GST pi
levels in the plasma (figure 4j) show that a centrifugal force greater than 2000 x g is
























Figure 4j: Effect of centrifugal force on plasma GST pi levels.
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4.10 : GST pi levels in platelet-poor and platelet-rich plasma
Samples of blood (18 mL) were taken without venous stasis from 12 healthy volunteers
and added to 2 mL of a solution containing citric acid (8 g/L), trisodium citrate (22 g/L)
and glucose (20 g/L) to prevent clotting. The blood was then divided into two equal
portions (A and B). This citrate anticoagulant was recommended for the collection of
platelet-rich plasma (Ludlam and Cash, 1976). Portion A was immediately centrifuged
at 120 x g for 10 min at room temperature and the upper portion of plasma collected.
Portion B was centrifuged at 2500 x g immediately at room temperature for 30 min;
only the middle portion of plasma was collected. The samples were stored at -20 °C
before analysis. The mean concentration (± SD) of GST pi in platelet-rich plasma was
154 //g/L (± 20.2). In all the samples of platelet-poor plasma GST pi concentrations
were below 10 /jg/L.
4.11 : Levels of GST pi in normal serum
Blood (10 mL) was collected from eight healthy volunteers into plain glass tubes and
left to clot (1 h) at room temperature before centrifugation at 3500 x g for 30 min at
4 °C. Serum was removed immediately and stored at -20°C until analysis. The mean
GST pi level in 8 sera was 16 /jg/L (range 8-30 /ug/L).
4.12 : Radioimmunoassay of Platelet Factor Four
Platelet factor four (PF4) was carried out, essentially, according to the manufacturers
instructions (Abbott Laboratories, Maidenhead, Berks., UK). All test reagents and
specimens were brought to room temperature before beginning the test. Tubes were
labelled for the performance of the test as follows:
a) Tubes 1 & 2, Total Count Tubes, for the determination of total
radioactivity.
b) Tubes 3 & 4, Nonspecific Binding (NSB).
c) Tubes 5 to 14, for the appropriate standards in duplicate.
d) Tubes 15, etc. for the unknown specimens in duplicate.
Standard or unknown (25 juI) was incubated with 125I-PF4 (125 fjL) and antiserum
(125 fjL) for 2 h at room temperature. Following this incubation, 0.5 mL of ammonium
sulphate solution (73% saturated) was added to all tubes (bar numbers 1 & 2) and
alloweu to stand for 15-20 min, before centrifugation (3000 x g, at 4 °C) for 30 min.
The supernatant was carefully decanted and the precipitate counted in a LKB 1261
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Multigamma gamma counter and the data processing performed using the LKB 1224-
Ria Calc. LM RIA evaluation program (LKB-Products, Bromma, Sweden).
4.13 : Effect of delay in centrifuqinq samples, collected into 'Thrombotect'
tubes, on GST pi and PF, levels
Blood (20 mL) was collected without venous stasis from six healthy volunteers into
'Thrombotect' blood collection tubes (Abbott Laboratories, Maidenhead, Berks., UK),
containing ethylenediaminetetra-acetic acid, 2-chloroadenosine and procaine/HCI;
these additives prevented coagulation and platelet activation. The blood was
portioned and left at room temperature for 0, 2, 4, 5 and 6 h before centrifugation
(3500 x g for 30 min at 4 °C). Plasma was removed and stored at -20 °C before
analysis for GST pi and PF4. Figure 4k illustrates the mean (± SE) levels for the
analytes during the time course studied.
Figure 4k: Illustration of how GST pi and PF4 concentrations increase with time,
between sample collection and centrifugation.
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4.14 : Investigation of plasma GST pi levels in patients with cancer of the
bronchus
Control groups: Two control populations were studied, a group composed of healthy
volunteers (n=26), and a group composed of patients with respiratory disorders other
than cancer of the bronchus (n=16). The latter group consisted predominantly of
sufferers from chronic obstructive airways disease and patients with pneumonia.
Lung cancer patients: Table 4c gives details of the 29 patients diagnosed as having
carcinoma of the bronchus included in this study.
Blood samples were collected from atraumatic venepunctures with minimal
venous occlusion and placed into 'thrombotect' blood collection tubes. The specimen
tubes were labelled with the patient's name and the exact time the blood was taken.
This labelling established whether the sample was received in the laboratory quickly
enough for analysis (within 2 h). When received in the laboratory the specimens were
immediately centrifuged for 30 min at 3000 x g (4 °C) and stored at -20 °C until
analysis. In addition to measuring GST pi concentrations, PF4 levels were also
measured. The assay of PF4, an 8000 dalton protein that is secreted from the
a-granules of blood platelets during the release reaction, was used to determine that
appropriate sample collection and separation procedures had been followed and that
no platelet activation had occurred. Any sample with a PF4 concentration greater than
50 pg/L was excluded from the study. In practice, once the collection procedure had
been established, only one sample with a high PF4 concentration was encountered.
The GST pi level in all 26 healthy volunteers was less than 10 pg/L.
Figure 41. illustrates the individual GST pi levels in the lung cancer patients (mean ±
SE = 23 ± 7.2 pg/L) and the respiratory disease group (mean ± SE = 9 ± 0.7 pg/L).
The median levels for the control group and the tumour group were 9 and 15 pg/L
respectively. Utilizing a Mann-Whitney non-parametric test, the probability that the
control group was different from the tumour group was P<0.01. The mean GST pi
levels in the squamous cell carcinoma (n = 11), adenocarcinoma (n=9) and small cell
carcinoma (excluding patient 23) (n=5) were 12.3, 24.0 and 16.5, pg/L respectively.
Eight out of 9 patients (89%) with adenocarcinoma had raised levels of plasma GST pi,
whereas, only 3 out of 6 patients with small cell carcinomas and 6 out of 11 (but one
was only 11 pg/L) of squamous carcinomas had elevated plasma GST pi
concentrations. The one patient with large cell carcinoma had a plasma GST pi































Patient characteristics and GST pi concentrations in the lung cancer
group.
Sex Age Tumour TvDe GST Di (uq/L) PF. I
M 60 Squamous 15 42
M 82 Squamous 8 50
M 81 Squamous 22 23
M 61 Squamous 7 49
F 43 Squamous 9 28
M 72 Squamous 21 15
F 52 Squamous 6 11
M 63 Squamous 11 <10
M 79 Squamous 5 <10
M 73 Squamous 21 50
M 67 Squamous 15 <10
M 76 Large Cell 8 <10
M 77 Adenocarcinoma 26 <10
F 67 Adenocarcinoma 14 <10
M 59 Adenocarcinoma 28 <10
F 66 Adenocarcinoma 18 25
M 63 Adenocarcinoma 33 <10
M 74 Adenocarcinoma 48 41
M 67 Adenocarcinoma 5 34
M 71 Adenocarcinoma 16 23
M 67 Adenocarcinoma 28 <10
M 53 Small Cell 10 <10
M 50 Small Cell 220 <10
F 65 Small Cell 6 <10
M 65 Small Cell 37 <10
F 68 Small Cell 13 <10
F 53 Small Cell 4 13
M 76 Histology inconclusive 16 38
































Figure 41: GST pi concentrations in 16 patients with benign respiratory disease
and 29 patients with carcinoma of the bronchus. Small cell,
squamous, large cell and adenocarcinoma are represented by o
and o respectively. The 2 carcinomas of unknown type are represented
by a A. Upper limit of reference range = 10 pg/L.
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4.15 : Discussion
In this section, the development of a radioimmunoassay capable of measuring GST pi
levels in plasma has been described. Antisera raised in eight separate rabbits to either
lung or placental GST pi each showed 100% cross-reactivity with GST pi purified from
placenta, lung or erythrocyte. This data coupled with the data from section 3 on the
physicochemical properties of the enzyme, support the widely held view that GST n
(placenta), A (lung) and p (erythrocyte) are products of the same gene. The
radioimmunoassay described here is specific for GST pi and demonstrates no cross-
reactivity with the other human GST isoenzymes tested. The fact the antibodies did
not cross-react with either the rat or mouse GST Yf is a demonstration of the specificity
of the RIA technique. Kano et al (1987), looking at the structure and expression of the
human GST pi mRNA and rat GST Yf mRNA deduced that both rat and human Yf
subunits consist of 209 amino acids and they differ in only 30 amino acids (85.6%
homology). Homology between different class GST (ie alpha, mu and pi), within the
same species (rat), is only about 30% (Pickett et al., 1984; Lai et a/.,1986; Sugioka et
al., 1985).
In order to maintain optimal conditions for the RIA it was necessary to introduce
an additional FPLC purification step for stored placental GST pi, because it became
apparent that the purified GST pi, used for iodination, gave poor binding and precision
when stored for more than 6 months. Chromatography of GST pi on the Mono Q
anion-exchange column was employed as Radulovic and Kulkarni (1986) had reported
separation of different interconvertible charge isomers of GST pi on a high
performance liquid chromatography anion-exchange column. Whether the two peaks
seen in figure 4a relate to the different charge isomers reported by Radulovic and
Kulkarni (1986), or are simply the products of oxidation, is not known.
The data presented (figures 4h-j) illustrates the necessity for a strict sampling
protocol if falsely elevated plasma GST pi levels are to be avoided. Delay in
separation of plasma, or the use of an inadequate centrifugal force resulted in marked
increases in the plasma concentration of GST pi probably as a result of the release of
platelet GST pi into plasma. Federici et al (1985) and Loscalzo & Freedman (1986)
have purified and characterised GST pi from human platelets. The 15-fold difference in
GST pi which is measured between platelet-poor and platelet-rich plasma indicates that
it is platelet GST pi which contributes to the marked elevation of GST pi plasma leveu,
unless whole blood is centrifuged immediately after collection and with sufficient
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centrifugal force. The introduction of 'Thrombotect' blood collection tubes inhibits
platelet activation and hence the release of GST pi for up to 2 h (figure 4j), thus
making collection of blood specimens more convenient and reliable. The assay of PF4,
an 8000 dalton protein that is secreted from the a-granules of blood platelets during
the release reaction, was used to check that appropriate sample collection and
separation procedures had been followed. From figure 4j it was concluded that
significant release of GST pi from platelets did not occur until levels of PF4 reached
100 pg/L, however an arbitrary cut of value of 50 qg/L for PF4 concentrations was
employed, samples with levels above 50 /jg/L were excluded.
The value of serum but not plasma GST pi concentrations as tumour marker
for gastrointestinal malignancies has been assessed (Niitsu et al., 1989; Tsuchida et
at., 1989). Niitsu et al. observed elevated serum GST pi levels in patients with gastric,
oesophageal, colonic, pancreatic, hepatocellular, and biliary tract cancers employing a
immunoradiometric assay and suggested that it was a good tumour marker. Tsuchida
et al., employing an enzyme-linked immunosorbent assay, reported increased serum
GST pi concentrations oesophageal cancer and pregnancy but not in lung cancer.
Table 4c indicates, however, that the use of serum, rather than plasma obtained using
'Thrombotect' tubes, is inappropriate since platelet-derived GST would obscure any
small increase in plasma GST pi produced by a tumour. Indeed, when GST pi was
measured in serum from normal subjects, concentrations up to three times the upper
level of the reference range from plasma were found. If an upper limit of 30 pg/L had
been used for the reference range, which represents the highest value we measured in
normal serum, only 4 out of the 29 cancer patients would have had elevated values for
GST pi (Table 4c).
Using 'Thrombotect' tubes, a good discrimination between cancer and non-
cancer patients could be made, with 19 cancer patients (66%) having elevated GST pi
concentrations. It is perhaps significant that 8 out of 9 (89%) adenocarcinomas had
elevated GST pi levels. A study (Rodenhuis et al., 1987) has reported that out of 10
adenocarcinoma 5 had activated K-ras oncogenes; no ras gene mutations were
observed in 15 squamous or 10 large cell carcinomas. In our study only 6 out of 11 of
squamous carcinomas had modestly raised GST pi levels.
The GST pi gene contains an AP1 regulatory element 5' to the coding region
(Cowell et al., 19u3) indicating that the induction of GST pi may be mediated through a
ras responsive transcription. An inducible v-H-ras fusion gene, introduced into rat liver
epithelial cells, has been shown to elevate the levels of GST pi (Burt et al., 1988). The
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greater plasma concentrations of GST pi in adenocarcinoma as compared to
squamous carcinoma is also in agreement with mRNA levels in tumour tissue. In a
comparison of normal versus tumour tissue, a 2.6 fold increase of GST pi mRNA in
adenocarcinoma was observed compared to a 1.8 fold increase in squamous
carcinoma (Moscow eta/., 1989).
Greater numbers of different classes of lung tumour types are required to
evaluate fully the clinical usefulness of plasma GST pi measurements. Also the results
of the tumour cytosol study described in section 6 and reports in the literature of
increased GST pi levels in various tumour tissues warrant further investigation of
plasma levels of GST pi. The radioimmunoassay for GST pi described here has
sufficient precision, specificity and sensitivity to enable any changes that may occur in
malignancy to be detected.
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Section 5 MEASUREMENT OF GST ISOENZYMES IN HUMAN BREAST
CANCER CYTOSOLS
5.01 : Oestrogen receptors and breast cancer
Oestrogen receptors (ER) are specific oestrogen-binding proteins, termed oestrophilin,
that are located in the cytoplasm and nucleus of oestrogen-responsive breast cells.
Oestrogen receptors must be present for oestrogen to influence the biological activity
and growth rate of breast tissue cells by increasing the production of mRNA and its
subsequent translation into the corresponding protein. Approximately 50-70 % of
female breast cancers have been found to contain oestrogen receptors. Although
oestrophilins may exist in normal breast tissue to regulate breast tissue development
during puberty and pregnancy, they are not usually present at measurable levels. The
presence (ER-rich) or absence (ER-poor) of receptor protein and the concentration
(estimated from the number of binding sites) in breast tumour tissue are established
prognostic factors in the clinical course of breast cancer. Oestrogen receptor positive
breast tumours are associated with improved response to hormonal therapy, longer
disease-free intervals, and improved survival (McGuire et al., 1975a&b; Nicolson era/.,
1981; Hawkins et al., 1987; Courdi etal., 1988).
5.02 : Association of ER status and GST pi
Using a cDNA probe, over-expression of GST pi mRNA has been found in a multi-drug
resistant human breast cancer cell-line (Moscow etal., 1988). The development of
multidrug resistance in this adriamycin-resistant (Adr") MCF7 human breast cancer cell
line is associated with a 45-fold increase in GST pi activity and with a concomitant loss
of ER and hormonal sensitivity (Batist et al., 1986; Cowan et al., 1986). Moscow et al.
(1988) also studied other breast cancer cell lines that were not selected for drug
resistance, in each of these 5 additional cell lines an inverse relationship between GST
pi activity and ER content was found. These same workers also examined the
expression of GST pi mRNA in a small series of 21 breast cancers and again an
inverse correlation between expression of GST pi and the ER levels in these tumours
was reported.
Although GST pi mRNA is increased, it is not known if this is translated into a
functional protein. Also the effects of ER status on the expression of the alpha or mu-
class GST at the mRNA, DNA or protein levels have not been investigated. The
studies reported in this chapter were performed to ascertain whether GST pi at the
protein level has an inverse relationship with ER-poor tumours and to determine if GST
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B1y B2 or n have any association with ER status. The rate of GST p expression in
breast cancer was also determined to discover if, when compared to a disease free
population, a greater or lower proportion of patients with breast cancer were nulled for
this polymorphic GST isoenzyme.
5.03 : Breast tumour cvtosol preparation
Cytosols were prepared from 58 breast tumours that had been stored in liquid nitrogen.
All procedures were performed at 0 to 4 °C. Tumour tissue was dissected from
surrounding fat and connective tissue, finely cut with scissors and homogenised in 20
mmol/L Tris buffer pH 7.5 (w/v 1:10) using a Silverson homogeniser at maximum speed
on 20 sec, then 15 sec with 1 min intervals for cooling. The homogenate was then
centrifuged at 105 000 x g for 1 h and the resultant supernatant was used as a cytosol.
5.04 : Measurement of oestrogen receptors
Oestrogen receptors were measured in an adjacent portion of tumour by saturation
analysis (Hawkins et al., 1981). Tumour cytosol was incubated overnight at 4 °C with
[3H] 17/5-oestradiol. Separation of free and bound fraction was measured by liquid
scintillation counting. Concentration of receptors was determined by Scatchard
analysis (Scatchard, 1949). Activities below 20 fmol/mg cytosolic protein were
designated ER-poor and those with activities in excess of 20 fmol/mg cytosolic protein
as ER-rich.
5.05 : Measurement of GST concentrations in breast tumour cvtosols
The specific radioimmunoassays for GST pi, B,, B2 and p described in sections 2 and
4 were used to measure the GST isoenzymes. The cytosol, if required , was diluted in
assay diluent consisting of 25 mmol/L sodium phosphate pH 7.6 bovine serum albumin
(1 g/L) and sodium azide (0.2 g/L) before analysis.
5.06 : Protein measurement
The dye binding technique described by Bradford (1976) and adapted for use on a




Glutathione S-transferase pi, B, and B2 were detected in all 58 breast tumour cytosols,
GST n was only detected in 28 (48%) of the cytosols. Table 5a summarizes the GST
isoenzyme levels obtained.
Table 5a: GST levels in breast cancer cytosols. Results are expressed as
yg GST/g protein. For GST p, data is given for only the 28 tumours
that express the protein (15 ER-rich & 13 ER-poor). The levels of GST
pi were significantly higher in ER-poor tumours (P<0.01, Mann-Whitney
U test) as compared to levels in ER-rich tumours.
GST B, GSTB2 GST pi GST p
mean median mean median mean median mean median
(±SD1 (±SD) (±SD) (±SD)
All tumours 8.5 4.5 1.2 0.86 294 222 174 118
(n=58) (±10.7) (±1.1) (±217) (±174)
ER-rich 5.2 3.6 1.0 0.98 208 198 264 183
(n=28) (±4.6) (±0.7) (±76) (±210)
ER-poor 11.6 4.7 1.4 0.82 374 306 160 107
(n=30) (±13.6) (±1.3) (±271) (±122)
Glutathione S-transferase pi was expressed most strongly with concentrations
ranging from 30 to 1110 pg/g. For the alpha-class GST B, and B2 concentrations
ranged from 0.6 to 48 pg/g cytosolic protein and 0.04 to 5.3 pg/g cytosolic protein
respectively. Glutathione S-transferase p concentrations, when expressed, ranged
from 18 to 576 pg/g cytosolic protein. Indeed, GST p was the most predominant GST
isoenzyme present in 9 out of the 28 tumour cytosols that expressed the protein. A
significant correlation, utilizing Pearson's correlation analysis (r=0.66, P<0.001), was
observed between levels of GST B, and B2. A summary of the other correlation
coefficients are given it■ table 5b.
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Table 5b: Summary of Pearson correlation coefficients between GST pi, B1t B2, p
and ER concentrations for the 58 breast tumours except for
correlations with GST p where only the 28 tumours expressing GST p
were used.
GST pi GST B, GST B2 GST p ER
GST pi 1 0.37** 0.24*** -0.18 -0.24'
GST B1 1 0.66* -0.16 -0.26'
GST B2 1 0.22 -0.18
GST p 1 0.38'
><0.001, *><0.002, **><0.05.
Concentrations of GST in the cytosols subdivided according to the ER status as
shown in figure 5a. The levels of GST pi were significantly higher in ER-poor tumours
(P<0.01, Mann-Whitney U test) as compared to levels in ER-rich tumours. The
tumours with the 11 highest GST pi values (>400 pg GST/g cytosolic protein, the
highest GST pi concentration seen in ER-rich tumours) were all in the ER-poor
tumours. As with GST pi the highest levels of GST B, and B2 were observed in the ER-
poor tumours with the eight highest GST B, levels being found in the ER-poor tumour
group. However when compared as groups the difference in the alpha-class GST
between ER-rich and ER-poor tumours did not reach statistical significance. Minor
correlations could be found in the quantitative levels of oestrogen receptors and the
expression of the GST isoenzymes (table 5b). However, no correlation was found
between ER level, in the ER-rich group, and each of the GST isoenzymes.
The frequency with which GST p was expressed in the breast cancers (48%) was
not significantly different from the frequency of expression of GST p found using
lymphocytes obtained from a group of 42 laboratory volunteers (described in section 7)
where 23 (55%) volunteers expressed the enzyme (Chi square = 0.19; P=0.66). Also
no association was found between GST p and ER status, GST p was present in 15 of
the 30 ER-poor tumours and 13 of the 28 ER-rich tumours.
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The same pattern of GST expression between groups was observed if a level of
>5 fmol/mg was used to define ER status. In the literature the cut-off for defining
whether a tissue is ER-rich or -poor varies from >5 to >30 fmol/mg. Three tumours
would have been reclassified as ER-rich, had a cut-off of >5 fmol/mg been employed.
All 3 samples had GST pi, B, and B2 concentrations which overlapped whether they
were classified in the ER-rich or -poor group. Two of the samples expressed GST fj,
however this did not effect the expression rate of this isoenzyme, for either group
significantly.
Although patient details were not available on all samples, there was no
relationship between GST levels and the age or menopausal status of the patient from
whom the sample had been derived. Likewise, no apparent association could be
determined between GST levels and lymph node involvement or tumour T stage in the
group of patients for whom this information was available. Similarly no special













































5a: Concentrations of GST B,, B2, pi and y in oestrogen rich (ER+) and
oestrogen poor (ER-) breast tumours (•). Tumours in which the
concentration of GST pi exceeded 400 pg/g cytosolic protein are shown
by (o).
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5.08 : Discussion of GST levels in breast tumour cvtosols
In this study, all three classes of GST isoenzymes were detected in breast cancer
cytosols, whereas Di llio et al., (1986) reported that only GST pi was present in normal
or tumour breast cytosols. Although, GST pi was the major GST isoenzyme
encountered in the majority of cytosols examined, GST yu when expressed had levels
approximately 50 % that of GST pi. The levels of alpha-class GST recorded in this
study were low (see section 6 for a comparison with other organs) and thus it is not
surprising that Di llio et al., (1986) did not detect alpha-class GST by GSH-affinity
column and chromatofocusing chromatography. The observation that higher GST pi
concentrations are found in ER-poor breast cancers as compared to ER-rich are in
agreement with the data of Moscow et al. (1988), who showed increased mRNA levels
for GST pi in a similar group of patients. The increased GST pi concentrations in the
cytosol indicates that the mRNA is being translated. In addition, to the GST pi data, it
has also been shown here, that the alpha-class GST appear to be expressed in greater
concentrations in ER-poor as compared to ER-rich breast tumours.
ER-poor tumours have been associated with a worse prognosis than ER-rich
tumours. Whether this observation is due to ER-poor tumours having a higher
proliferation rate (Meyer et al., 1977) of the two types of tumours or is simply due to
differences in the sensitivity of these tumours to chemotherapeutic agents is not clear.
The evidence that GST are associated with the phenomena of drug resistance is
substantial (for a review see Hayes & Wolf, 1988). Therefore the finding of increased
GST pi in ER-poor tumours may add weight to the theory that ER-poor tumours are
more resistant to chemotherapy, however GST pi as yet, has not been implicated in the
direct metabolism of any anticancer therapeutic agent.
The ligand-binding properties of GST rather than their detoxification properties
may be important in cellular protection. The GST have been shown to bind steroid
hormones including, corticosterone, testosterone, progesterone and 17/S-oestradiol (for
a review see Listowsky et al., 1988). These binding experiments were performed by
circular dichroism spectra of rat Yb2-GST-bilirubin complex to study the competitive
displacement of bilirubin from the protein by other ligands (Kamisaka et al., 1975).
This same work, reports that the rat Yb2 GST has a weak affinity for tamoxifen the
drug currently used in the hormonal deprivation therapy of breast tumours. Tamoxifen
acts by irreversibly binding the ER thus blocking the any possible action of 17yS-
oestradiol on the nucleus. Rat Yb2 GST a mu-class GST, may have completely
different binding characteristics than human Yf (GST pi) GST.
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It should be emphasised that whereas the majority of ER-poor tumours rarely
respond to hormone manipulation (Le Clercq & Heuson, 1977), in this study only a
small proportion of ER-poor tumours had elevated levels of GST. In this respect the
observation that ER-poor breast cancers can be further subdivided into groups on the
basis of other tumour characteristics such as epidermal growth factor receptors,
vimentin and p53 expression (Cattoretti et al., 1988) is probably relevant.
Unfortunately, I did not measure these parameters and therefore cannot conclude if
there is an association between GST pi expression and epidermal growth factor
receptor levels. It would have been of interest to know whether the patients with
tumours expressing the higher levels of GST return more quickly with recurrent disease
than those with lower GST, irrespective of ER status but follow up details were not
available.
A study involving the assessment of GST expression in a series of 86 primary
human breast cancers by an immunohistochemical method (Cairns et at., 1989),
concluded that their results did not support the hypothesis that local levels of GST
determine response to chemotherapy. An association was observed between GST pi
staining and histological grade and stromal elements (eg. presence of fibroblasts,
inflammatory cells), no reference to ER status was made. The possibility that in this
study, the elevated GST pi concentrations are primarily due to stromal effects is
unlikely as with 58 samples one would have expected to see an equal distribution in
ER-poor or ER-rich groups of stromal elements. The immunohistological technique
only detected the alpha-, mu- and pi-class GST in 13, 51 and 43 % of the breast
tumours respectively whereas I was able to detect the alpha- and pi-class GST in all
samples. This difference is probably due to the different sensitivities of the two
techniques and raises the question whether immunohistochemistry is a sensitive
enough technique to look at the small differences in expression of GST shown in
breast cancers.
Glutathione S-transferase pi maps to chromosome 11 (Moscow et al., 1988) which
has an increased incidence of deletions in ER-poor tumour cells when compared to
ER-rich tumours (Ali et al., 1987). These observations have led to the suggestion of a
link between over-expression of GST pi and a specific deletion on chromosome 11.
The alpha-class of GST, however, map to chromosome 6 (Board & Webb, 1987) and
this data shows that both GST B, and GST B2 are also over-expressed in a number of
ER-poor tumours. This suggests that there may be a common mechanism rather than
specific chromosomal deletions that leads to the elevation of GST concentrations in
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certain breast cancers.
The incidence of GST n expression in both the ER-poor and ER-rich breast
tumours was not significantly different from the incidence of GST expression found in
lymphocytes from the normal population. Heavy smokers are reported to be more
susceptible to lung cancer if they lack GST ^ (Seidegard et al., 1986). The results of
this study indicate there is no association between expression of GST n and
susceptibility to breast cancer.
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Section 6 GLUTATHIONE S-TRANSFERASE LEVELS AND
GLUTATHIONE PEROXIDASE ACTIVITIES IN HUMAN
TUMOURS
The central role of the glutathione S-transferases and glutathione peroxidase in
chemical detoxification has led to the recognition that these proteins are probably
involved in the sensitivity of tumours to the therapeutic effects of anticancer drugs
(Hayes and Wolf, 1988). There is an increasing body of evidence to indicate that this
is indeed the case. For example, cell lines made resistant to anticancer drugs over-
express GST proteins (Batist eta/., 1986; Robson et al., 1987; Lewis et al., 1988; Wang
and Tew, 1985). In one report this has been shown to be due to an amplification of an
alpha-class GST (Lewis et al., 1988). It has also been recently shown that the
expression of human alpha- or pi-class cDNA in yeast confers resistance to the
anticancer drugs chlorambucil and adriamycin (Black et al., 1989). On the basis of this
direct evidence, that these proteins will be a factor in chemotherapy, it is important to
establish the levels of GST isoenzymes in human tumours.
There have been several reports on the expression of GST mRNA or protein in
human tumours (Carmichael et al., 1988; Di llio et al., 1988b; Di llio et al., 1987a;
Eimoto et al., 1988; Moscow et al., 1989). However, most of these deal only with the
GST pi isoenzyme. In order to examine further the GST expression in normal and
tumour human tissue, in this study, the composition of glutathione S-transferase (GST)
isoenzymes in human normal and tumorous lung, colon, stomach, breast, kidney and
liver tissue have been examined by a variety of techniques. The levels of GST activity
were assessed by measuring the rate of conjugation between 1 -chloro-2,4-
dinitrobenzene (CDNB) and glutathione. In addition, selenium-dependent and
independent glutathione peroxidase activities were measured in the tissues using
hydrogen peroxide (H202) and cumene hydroperoxide (CuOOH) as substrates,
respectively. Individual subunit quantification was performed by the sensitive and
specific technique of radioimmunoassay (RIA). Western blot analysis, probing with
antisera from the three different classes of GST alpha, mu and pi, was employed to
check for any novel polypeptides highlighted by these antisera.
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6.01 : Matched normal and tumour cvtosol preparation
Tumour and adjacent normal tissue from patients who had not received prior
chemotherapy, were obtained at surgery. Tissues were analysed and dissected by
surgical pathology. Matched tumour and normal tissue from lung (19), colon (27),
stomach (9), breast (18), and kidney (7) was collected. The lung tumours comprised 7
adenocarcinomas, 6 squamous carcinomas, 3 large cell carcinomas, 1 carcinoid, 1
mesothelioma and a metastatic histiocytoma from the thigh. Three primary liver
tumours were also collected but matched normal tissue was not available; instead, 3
pieces of normal liver from patients without tumours were obtained (kidney transplant
donors). All tissues were placed on ice in RPMI 1640 media for transport to the
laboratory and frozen within 30 min in liquid nitrogen and stored at -70 °C until
required. Specimens were allowed to thaw at 20 °C and 20% homogenates (w/v)
were prepared in ice-cold 0.25 M sucrose. The homogenates were then centrifuged
for 15 min at 10 000 x g, followed by 60 min at 100 000 x g. Final supernatants were
collected and are referred to as cytosols.
Although tissue obtained from a site adjacent to tumour tissue may not
represent true 'normal' tissue, due to the effects of growth factors or hormones
possibly secreted by the tumour mass, in this study the term normal represents non-
tumour tissue.
6.02 : Glutathione S-transferase activity
Measurement of GST enzymic activity was determined using 1 -chloro-2,4-
dinitrobenzene (CDNB) as substrate. The assay was carried out at 37 °C, in duplicate,
using 1 mM CDNB and 2 Mm reduced glutathione on a Cobas Fara centrifugal
analyzer (Roche Diagnostics Ltd., Basle, Switzerland) (Hayes and Clarkson, 1982) as
described in Section 2.
6.03 : Glutathione peroxidase assays
Measurement of selenium-dependent (sGPX) and total glutathione peroxidase (tGPX)
utilised an adaptation of the Paglia and Valentine (1967) method for use on a Cobas
Fara centrifugal analyzer, as described in Section 2. Hydrogen peroxide (H202) was
the substrate employed to measure sGPX whereas, cumene hydroperoxide (CuOOH)
was the substrate employed to measure tGPX.
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